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Abstract
This dissertation is focused on the assessment of glucose variability (GV) in the treat-
ment of the pathology of diabetes mellitus. GV is a risk factor for the development of
diabetes complications, and its assessment combined with the evaluation of glycated
hemoglobin levels is believed to be useful to characterize the functioning of glucose
metabolism. Given the importance of GV in diabetes, a number of indicators to
measure it from the retrospective analysis of sparse self-monitoring of blood glucose
(SMBG) or continuous glucose monitoring (CGM) recordings have been proposed in
the literature, but several issues are still open. For instance, some GV indicators have
been developed specifically from SMBG data, and their use on CGM time-series has
not been validated yet. Moreover, the availability of a large number of metrics to
quantify GV gives rise to problems in terms of redundant conveyed information, and a
compact way to extensively characterize GV would be desirable. Finally, the exploita-
tion of CGM signals and GV to classify the metabolic condition of normal and diabetic
subjects is a relatively unexplored problem that could deserve an investigation. These
three topics are the object of this dissertation, which is specifically made up of six
chapters whose content is briefly outlined below.
Chapter 1 will describe the etiology of the different types of diabetes, discuss the de-
velopment of diabetes complications, and introduce the technologies used to monitor
blood glucose levels and the strategies exploited to manage the treatment of type 1
(T1DM) and type 2 (T2DM) diabetes mellitus.
Chapter 2 will focus specifically on GV and its quantification, and, after highlighting
the existing open issues, will precisely state the aims of the thesis.
Chapter 3 will consider the problem of adapting some GV indicators originally de-
veloped and validated from SMBG, to the use with CGM signals. In particular, we
will specifically look at low blood glucose index (LBGI) and high blood glucose index
(HBGI), popular metrics that allow to provide a rapid classification of the quality
of glucose control in diabetic subjects, and will provide alternate versions of these
indicators adapted to the characteristics of CGMs by modeling the relationship be-
tween LBGI/HBGI values obtained from SMBG and CGM recordings. A dataset of
vii
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28 T1DM subjects monitored with both SMBG and CGM devices will be used to tune
and assess the proposed methodology.
Chapter 4 will address the issue of redundant information conveyed by the available
GV indices by using the sparse principal component analysis (SPCA) technique as a
tool to provide a parsimonious but still comprehensive characterization of GV in both
T1DM and T2DM. Specifically, we will consider 25 GV indicators evaluated on CGM
profiles acquired from 33 T1DM and 13 T2DM subjects as initial pool of variables.
SPCA will be applied to this set of metrics and will be shown to be able to select a
small subset of up to 10 indices that can save more than 60% of the original variance
in both applications. The subset of metrics provided by SPCA can be used to parsi-
moniously describe GV in diabetes.
Chapter 5 will be devoted to the assessment of the possibility of using the outputs from
SPCA to build GV-based classifiers of the metabolic condition of normal and diabetic
subjects. In particular, by resorting to a dataset of 55 T1DM subjects, 34 normal
subjects at high risk of developing T2DM, 39 impaired glucose tolerance subjects, and
29 subjects with T2DM diagnosed, we will show that support vector machines are able
to successfully classify the quality of glycemic control and the metabolic condition of
disordered subjects, allowing to achieve an accuracy of classification always greater
than 70%. The investigation will be performed using both the whole initial pool of
25 indicators and the parsimonious set selected by SPCA as features to design the
classifiers; the fact that similar results were obtained in the two scenarios strengthens
the speculation that the compact description of GV provided by SPCA is effectively
comprehensive for characterizing the subjects’ metabolic condition.
Chapter 6 will close this dissertation, with a discussion on possible future developments
of the presented investigations.
Sommario
L’obiettivo di questa tesi e` l’indagine del ruolo della variabilita` glicemica (GV) nella
patologia del diabete mellito. La GV e` un fattore di rischio per lo sviluppo di compli-
cazioni dal diabete, e la sua valutazione combinata con quella dei livelli di emoglobina
glicata e` ritenuta essere un elemento utile nel caratterizzare il funzionamento del
metabolismo del glucosio. Data l’importanza della GV nel diabete, molteplici indi-
catori che permettono di ottenerne una quantificazione dall’analisi retrospettiva di
segnali di self-monitoring of blood glucose (SMBG) o continuous glucose monitoring
(CGM) sono stati proposti in letteratura, ma in merito esistono alcune problematiche
ancora aperte. Per esempio, alcuni indici sono stati sviluppati specificamente per essere
applicati su serie SMBG, ed il loro utilizzo su segnali CGM non e` ancora stato validato.
Inoltre, il fatto che esistano numerosi indicatori per quantificare la GV da` origine a
problemi di ridondanza nell’informazione trasmessa, ed un approccio che permetta di
ottenere una descrizione compatta ma esaustiva della GV sarebbe desiderabile. Infine,
l’uso di segnali CGM e dell’informazione sulla GV per classificare lo stato metabolico
di soggetti normali e diabetici e` un problema relativamente inesplorato che potrebbe
meritare di essere trattato. Questi tre argomenti sono l’oggetto di questa tesi, che
risulta articolata in sei capitoli il cui contenuto e` brevemente delineato di seguito.
Il Capitolo 1 descrivera` l’eziologia dei differenti tipi di diabete, discutera` lo sviluppo
delle complicazioni da diabete, ed introdurra` le tecnologie utilizzate per monitorare la
glicemia ed alcune strategie che si possono seguire per trattare il diabete mellito di
tipo 1 (T1DM) e 2 (T2DM).
Il Capitolo 2 vertera` sulla GV e la sua quantificazione, e, dopo aver evidenziato i prob-
lemi aperti esistenti, dichiarera` precisamente gli scopi della tesi.
Il Capitolo 3 considerera` il problema di adattare alcuni indicatori di GV originaria-
mente sviluppati e validati su profili SMBG, all’utilizzo su segnali CGM. In partico-
lare, ci concentreremo su low blood glucose index (LBGI) e high blood glucose index
(HBGI), indici popolari che permettono di ottenere una rapida classificazione della
qualita` del controllo glicemico in soggetti diabetici, e forniremo versioni alternative
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di questi indicatori adattate alle caratteristiche dei segnali CGM, modellando la re-
lazione tra i valori che LBGI e HBGI assumono quando calcolati da SMBG e CGM. Un
dataset di 28 soggetti T1DM monitorati con dispositivi SMBG e CGM sara` utilizzato
per mettere a punto la metodologia.
Il Capitolo 4 affrontera` il problema della ridondanza nell’informazione fornita dagli
indicatori di GV esistenti, utilizzando la sparse principal component analysis (SPCA)
come approccio per fornire una descrizione parsimoniosa ma allo stesso tempo esaustiva
della GV in popolazioni di soggetti con T1DM e T2DM. In particolare, considereremo
25 indicatori di GV valutati su profili CGM acquisiti da 33 soggetti con T1DM e 13
con T2DM come insieme iniziale di variabili. La SPCA sara` applicata a questo pool
di indici e permettera` di selezionare un piccolo sottoinsieme di 10 indicatori che con-
sente di preservare piu` del 60% della varianza originariamente spiegata dall’insieme di
partenza in entrambe le applicazioni. Il sottoinsieme di indicatori fornito dalla SPCA
puo` essere utilizzato per descrivere parsimoniosamente la GV nel diabete.
Il Capitolo 5 sara` dedicato alla valutazione della possibilita` di utilizzare gli output
della SPCA per costruire classificatori dello stato metabolico di soggetti normali e dia-
betici basati sulla GV. In particolare, facendo ricorso ad un dataset di 55 soggetti con
T1DM, 34 normali a rischio T2DM, 39 con impaired glucose tolerance, e 29 con T2DM
diagnosticato, mostreremo che classificatori progettati su support vector machine sono
capaci di discriminare con successo la qualita` del controllo glicemico e la condizione
metabolica di soggetti con disordini, permettendo di raggiungere un’accuratezza di
classificazione sempre maggiore del 70%. Lo studio sara` condotto utilizzando sia il
pool iniziale di 25 indicatori che il sottoinsieme parsimonioso fornito dalla SPCA come
features per costruire i classificatori; il fatto che risultati simili siano ottenuti nei due
casi rafforza la speculazione che la descrizione compatta della GV fornita dalla SPCA
sia effettivamente esaustiva nel caratterizzare la condizione metabolica dei soggetti.
Il Capitolo 6 chiudera` la tesi, con una discussione su possibili sviluppi futuri degli studi
qui presentati.
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Chapter 1
The pathology of diabetes
and its monitoring
1.1 The pathology of diabetes
Diabetes is a metabolic disease resulting from defects in insulin secretion, insulin ac-
tion, or both [1]. Insulin is a hormone automatically released by the islets of Langer-
hans of the pancreatic beta-cells, that regulates the level of glucose concentration in
the blood and keeps it within the so-called euglycemic range, a healthy condition where
glycemia is between 70 and 180 mg/dL [2]. After a meal, glucose molecules derived
from the digestion of carbohydrates enter the bloodstream and rapidly increase the
subject’s glycemia. If properly secreted by the pancreas, insulin available in the blood
stimulates glucose uptake by various body tissues (e.g., muscles and adipose tissue)
and inhibits its production by the liver, reducing the level of glucose in the blood and
restoring a safe condition of euglycemia. Being the glucose uptake by certain tissues an
insulin-dependent process, the appearance of insulin in the bloodstream after a meal
is necessary to allow glucose molecules entering the cells, producing energy, and stim-
ulating growth. If no insulin is available in the bloodstream, or tissues are no more
sensitive to its action, only insulin-independent glucose uptake (e.g., by the brain)
can occur. This entails metabolic damages related to the lack of glucose provided for
the feeding of insulin-dependent cells and leads to chronic abnormally high levels of
glucose concentration in the blood that end up in a long-term damaging condition
known as hyperglycemia [1]. The scenario just described is what characterizes the
pathology of diabetes, where, depending on the specific type of disease, the system
producing insulin is progressively destroyed or the effectiveness of insulin action on
1
2 Chapter 1 The pathology of diabetes and its monitoring
glucose transportation through the cell membrane is impaired. To compensate the
defects in their glucose-insulin regulation system, beyond healthy diet and regular
physical activity, diabetic people may have to inject exogenous insulin multiple times
a day, especially when they eat, with the risk of overestimating the amount of insulin
needed to restore a euglycemic state, thus inducing an unsafe decrease of glucose levels
in the bloodstream. This condition, that is the opposite of the previously introduced
hyperglycemia, is known as hypoglycemia, and its occurrence represents an extremely
serious problem in the pathology of diabetes. Hypoglycemia is a medical emergency
where the abnormal reduction of glycemic levels degenerates into an inadequate supply
of glucose to the brain (neuroglycopenia) that, if severe and not properly treated, may
rapidly progress into coma and eventually into death, also without subject awareness
especially at night. Because of the potentially life-threatening damages associated to
hypoglycemia, the chance of its occurrence represents one of the most limiting factors
in following an intensive therapy to strongly reduce hyperglycemia and achieve a tight
glycemic control in the treatment of diabetes [3].
Risk associated with the extreme glycemic conditions experienced by diabetic people
and the massive diffusion of this pathology render diabetes an actual emergency of the
2000s, and numbers related to it are effectively alarming. As updated to November
2014, key facts from the World Health Organization [4] report that 347 million people
throughout the world suffer from diabetes, with an estimation of 1.5 million deaths
directly caused by diabetes in 2012, more than 80% of deaths occurring in low- and
middle-income countries, and projection of diabetes being the 7th leading cause of
death in 2030. As far as the American community is concerned [5], the prevalence of
diabetes in 2012 was 29.1 million people, i.e., 9.3% of the entire population, of whom
8.1 million were undiagnosed. In the same year, the incidence of diabetes was 1.7
million new diagnoses/year, while in 2010 it was 1.9 million. These numbers made di-
abetes the 7th leading cause of death in the United States in 2010, with 69,071 death
certificates listing it as the underlying cause of death, and a total of 234,051 death
certificates listing diabetes as an underlying or contributing cause of death.
1.2 Types of diabetes
Three different types of diabetes can be identified [1]. The two major ones are known
as type 1 and type 2 diabetes, the third one, less common, is known as gestational
diabetes. Moreover, intermediate conditions between normality and diabetes have
1.2 Types of diabetes 3
been also classified, and are known as impaired glucose tolerance and impaired fasting
glucose. They are all detailed below.
1.2.1 Type 1 diabetes mellitus (T1DM)
Type 1 diabetes mellitus (T1DM), also known as insulin-dependent diabetes, is an
autoimmune disorder that leads to the complete destruction of the insulin-producing
pancreatic beta cells [1]. People with T1DM become totally unable to produce in-
sulin and need to regularly take exogenous insulin to keep their glycemic levels con-
trolled. Approximately 5-10% of diabetic people are affected by T1DM [5]. Although
a large number of T1DM patients developed the condition during childhood (reason
why T1DM is also called juvenile or childhood diabetes), the pathology can appear
in people of any age [6, 7]. The cause of T1DM is not known, the pathology is not
preventable with current knowledge, the majority of people developing it are of normal
weight, and exercise and diet, though invaluable in the treatment of T1DM, cannot re-
verse this disorder [4, 7]. Several clinical trials have attempted to find ways to prevent
or slow down the progress of T1DM, but with no proven success so far [7].
1.2.2 Type 2 diabetes mellitus (T2DM)
People with type 2 diabetes mellitus (T2DM) are not able to produce enough insulin
or suffer from the so-called insulin resistance, condition where cells are not sensitive to
insulin action anymore and glucose cannot enter them as much as it would do in normal
subjects [1]. T2DM is the most common form of diabetes and about 90% of diabetic
people suffer from this type of disorder [4, 6, 7]. The majority of people with T2DM
have developed the condition because they are overweight and physically inactive,
reason why increased exercise and dietary changes can help in initially managing this
disease [7]. Since T2DM can be treated without the injection of exogenous insulin, it is
also called insulin-independent diabetes. Nevertheless, if the optimization of lifestyle
is not enough to control glycemic levels of T2DM subjects, administering medications
or insulin during the day could be necessary to treat T2DM as well [6, 7].
1.2.3 Gestational diabetes mellitus
Gestational diabetes mellitus (GDM) is a condition that occurs when a woman without
previously diagnosed diabetes exhibits high levels of glucose concentration in the blood
during pregnancy, usually around the 24th week [1, 7]. GDM complicates nearly 4%
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of all pregnancies in the United States, resulting in 135,000 cases annually [1]. The
prevalence may range from 1 to 14% of pregnancies, depending on the population
studied, and nearly 90% of all pregnancies complicated by diabetes are related to the
occurrence of GDM [1]. Specialists are not sure about the causes of GDM, but it
seems that hormones from the placenta that help the baby develop, also block the
action of the mother’s insulin in her body [7]. Thus, as for T2DM, women with
GDM suffer from insulin resistance, and may need up to three times as much insulin.
Mothers with untreated GDM are likely to develop T2DM after pregnancy and can
have babies abnormally large for gestational age (condition that may lead to delivery
complications) [7].
1.2.4 Pre-diabetes conditions
Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) are conditions
preceding the development of diabetes respectively associated with a state of hyper-
glycemia due to insulin resistance and a consistently elevated fasting glycemic level,
however not enough to prompt a diagnosis of diabetes [1]. Both these conditions in-
crease the risk of developing cardiovascular pathology and T2DM, with a greater risk
for IGT than for IFG [4]. Some patients with IFG can also be diagnosed with IGT,
but many have normal responses to a glucose tolerance test (medical procedure where
glucose is given to the patients and blood samples are taken afterwards to assess how
quickly glycemia goes back to normal values). Lifestyle modifications, regular physical
exercise, limited intake of sugar and highly processed carbohydrates, and loss of body
weight can delay the onset of diabetes [7].
1.3 Development of diabetes complications
The attempt of avoiding hyperglycemia and achieving a tight glycemic control is a
major goal in the treatment of diabetes, not only to ensure an adequate delivery of
glucose to insulin-dependent cells, but also to decrease the likelihood that body tissues
are harmed by prolonged high blood glucose (BG) levels. As detailed in the literature
[8–10], hyperglycemia represents a risk factor for the development of serious long-term
complications from diabetes, and its direct and indirect effects on the vascular tree have
been reported to be the major source of morbidity and mortality in both T1DM and
T2DM. The etiologic characteristics of diabetes complications are mostly related to
the role played by chronic hyperglycemia in initiating many metabolic and structural
1.4 Strategies for glucose monitoring 5
derangements, that include production of advanced glycation end products, abnor-
mal activation of signaling cascades, elevated production of reactive oxygen species
(oxygen-containing molecules that can interact with other biomolecules and result in
damaging oxidative stress), and abnormal stimulation of hemodynamic regulation sys-
tems [11]. These processes, combined with other factors, progress into specific diseases
that, depending on their nature, are usually classified as macrovascular or microvas-
cular diabetes complications.
The central pathological mechanism that entails macrovascular diseases is the process
of atherosclerosis, where plaques building up along the inner walls of the arteries nar-
row the lumen of vessels and reduce blood flow to target sites [8]. Atherosclerosis is
thought to result from chronic inflammation and injury of the arterial walls in the
cardiac, cerebral, and peripheral vascular system, and represents a potential cause of
deleterious conditions like coronary artery disease, myocardial infarction, cerebrovas-
cular disease, stroke, and peripheral arterial disease.
Beside damages to large vessels, prolonged hyperglycemia can cause a number of mi-
crovascular complications specific to diabetes that include retinopathy, nephropathy,
and neuropathy [9]. Among these harmful conditions, retinopathy, a potential cause
of visual impairment and blindness, is the most common injury. The majority of dia-
betic patients are affected by this disease, with approximately 50% of T1DM subjects
suffering from some degree of retinopathy after seven years, and 90% after 20 years.
Unlike retinopathy, nephropathy develops in only 35 to 45% of subjects with T1DM
and less than 20% of subjects with T2DM. This is the diabetes-specific complication
with the greatest mortality, and can lead to renal failure with potential progression
into end-stage renal disease. The third most common microvascular complication from
diabetes is neuropathy, that is associated to a number of clinical manifestations includ-
ing impairment of gastric or intestinal motility, impotence, and diabetic foot disorders.
The prevalence of neuropathy as defined by loss of ankle jerk reflexes is 7% at one year
of diabetes, increasing to 50% at 25 years for both T1DM and T2DM.
To treat diabetes and manage the occurrence of sustained hyperglycemia causing the
progression of complications, diabetic people have to frequently monitor their BG lev-
els. To this aim, two main strategies exist, which are discussed in the next section.
1.4 Strategies for glucose monitoring
In 1978, a study involving 64 diabetic patients demonstrated that the possibility of
measuring BG concentration at home using commercially available glucose meters
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could lead to a significant improvement of glycemic control [12]. Since that time,
the technology of glucose meters (Section 1.4.1) has evolved towards the nowadays
increasingly used glucose sensors (Section 1.4.2).
1.4.1 Self-monitoring of blood glucose (SMBG)
Self-monitoring of blood glucose (SMBG) devices are small, battery-operated glucose
meters that allow to measure the concentration of glucose from a drop of capillary blood
usually taken from a finger. When the subject wants to test for glucose, he needs to
prick his skin with a lancet, place a small sample of his blood on a reagent strip,
and determine the glucose concentration by inserting the strip into the meter (usually
a reflectance photometer) for an automatic reading [13]. After each measurement,
results are stored in the meter’s electronic memory. Examples of commercially available
SMBG devices are shown in the left panel of Figure 1.1; the right panel of the same
figure reports a representative SMBG profile collected from a T1DM subject for three
consecutive days together with hypo and hyperglycemic thresholds.
Figure 1.1 Examples of commercially available SMBG devices (left panel - taken
from [14]) and representative SMBG profile shown with hypo and hyperglycemic
thresholds at 70 and 180 mg/dL, respectively (right panel).
Through the use of SMBG devices, diabetic people have an immediate feedback about
their current glycemic level and can correct any deviation out of a desired target range
by changing the carbohydrate intake, exercising, or using more or less insulin. In this
context, it is clear that the sampling design (when and how frequently subjects measure
their glycemia) plays a major role in achieving a good glycemic control, avoiding
extreme hyperglycemia, and promptly treating hypoglycemic episodes. The frequency
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with which patients sample varies from person to person, but most experts agree
that insulin-treated diabetics should monitor their glycemic level at least four times a
day, most commonly fasting, before meals, and before bed, with a significant benefit
derived from collecting post-prandial BG readings to adjust insulin regimen [13]. In
general, a positive correlation between frequency of SMBG and glycemic control among
patients with insulin-treated T1DM or T2DM seems to hold [15, 16]. However, even if
BG levels are monitored through a full seven-point SMBG profile, the subject is still
unable to carefully track the evolution of his glycemic condition across the whole day
(see the right panel of Figure 1.1). This can lead to prolonged hyperglycemic states,
hypoglycemic attacks not promptly recognized and treated, especially in subjects with
hypoglycemia-unawareness, and information about glucose fluctuations totally missed
and not considered by the doctor in optimizing the ongoing therapy. To overcome
these limitations, a system to allow more-frequent (ideally continuous), less-invasive
BG measurements was necessary, and to satisfy these requirements the technology of
implantable glucose sensors has been developed since the early 2000s.
1.4.2 Continuous glucose monitoring (CGM)
Continuous glucose monitoring (CGM) systems are portable devices that allow an al-
most continuous monitoring of interstitial glycemia (sampling time of 1-5 minutes) for
up to seven consecutive days [17–21]. The substantially high sampling frequency of
these devices is possible thanks to the technology of implantable glucose sensors that,
together with a wireless transmitter and a receiver, are the core of CGM systems. The
left panel of Figure 1.2 shows an example CGM device; sensor and transmitter can
be seen in the upper part of the panel, from left to right, respectively; the receiver
is represented in the lower part. In practice, the sensor is inserted into the subcuta-
neous tissue (most commonly at the abdomen) and a reusable transmitter attached
to it relays the glucose data wirelessly to the receiver, where they are displayed. The
receiver, that allows to store several days of monitoring in its memory, may be a
dedicated handheld device or an insulin pump designed to integrate with CGM (the
so-called sensor-augmented insulin pump described in the next section). Either way,
looking at the monitor of the receiver, the user can track his glycemic levels in real time
and benefits from symbols indicating trends of stable, increasing, or decreasing glucose
status, together with a graphical representations of the evolution of his glycemia (see
the left panel of Figure 1.2). Beside the visual information, the devices also offer audi-
ble alarms to alert the patient when BG levels are below or above a preset safe range,
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to aid in identifying impending hypo or hyperglycemia. Together with an example of
CGM device, Figure 1.2 shows in its right panel a representative CGM profile collected
from the same subject as the SMBG samples of Figure 1.1. It is clear by comparing
the time-series that CGM sensors allow to capture glycemic excursions and hypo/hy-
perglycemic episodes that cannot be seen from sparse SMBG recordings.
Figure 1.2 Example of commercially available CGM device (left panel - taken from
[22]) and representative CGM profile shown with hypo and hyperglycemic thresholds
at 70 and 180 mg/dL, respectively (right panel).
The key element within CGM systems is of course represented by the glucose sensor. In
most of the currently available minimally-invasive CGM devices, the sensor exploited is
electrochemical and consists of a wire inserted subcutaneously into the back, buttocks,
or most commonly abdomen, that produces an electrical current correlating with the
interstitial glucose level. These sensors are amperometric systems that measure the
current flowing from an oxidation (electron producing) reaction at a working electrode
to a reduction (electron consuming) reaction at a counter electrode. The working elec-
trode is typically coated with the enzyme glucose oxidase that is necessary to oxidate
glucose and start the reaction sequence. The electrical current finally measured by the
sensor is proportional to the amount of glucose in the subcutis. Sensors are inserted by
the patient and can be immediately replaced after their useful lifetime. To be sure that
the sensor maintains its accuracy over time, the device needs to be often calibrated.
Sensor calibration is the transformation in real time of the electrical current signal
generated by the sensor at a certain time into an estimation of glucose concentration
[23]. The reference BG levels used to optimize the transformation are SMBG readings
conveniently collected and entered into the system’s monitor. All commercial CGM
sensors need to be calibrated through two SMBG readings when they are inserted at
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the beginning of their lifetime. Then, the minimum frequency of calibration required
is once every 12 hours, but calibrating three to four times a day can optimize sensor
accuracy. Having accurate glucose sensors within CGM systems is necessary also for
the role played by these devices in the development of the so-called artificial pancreas
(AP) [24]. The AP is a closed-loop control algorithm that automatically releases in-
sulin based on BG levels and other inputs. BG readings are provided by CGM devices,
and inaccurate measurements can lead to wrong insulin administration and occurrence
of unsafe conditions of hypoglycemia or hyperglycemia.
Beside their use within the AP, the possibility given by CGM devices to track BG
levels in real time has made an important difference in the treatment of diabetes.
When compared to traditional SMBG alone, the use of CGM systems has been shown
to significantly improve the quality of glycemic control, as quantified by the levels of
glycated hemoglobin (HbA1c), a measure related to the average glycemia over the 2-3
months preceding the test, and by the time spent in hypoglycemia [25, 26]. The use
of CGMs has been in particular recommended for T1DM adults seeking to improve
their HbA1c, control hypoglycemic episodes, and detect nocturnal hypoglycemia, early
morning hyperglycemia due to insulin resistance (the dawn phenomenon), and post-
prandial hyperglycemia [20, 27, 28]. Moreover, because of the high sampling frequency
and long-lasting duration of CGM recordings, glucose sensors represent a powerful
tool also for the retrospective investigation of the nowadays extremely debated glucose
variability, a risk factor for the development of long-term complications from diabetes
that will be carefully described in the next chapter and is the focus of this dissertation.
Components of glucose dynamics invisible in the SMBG profiles are, in fact, captured
in detail by CGM systems (compare the right panel of Figure 1.1 with the right panel
of 1.2), and the assessment of the time spent in hypo/hyperglycemia or of the am-
plitude of glucose fluctuations can be made on more reliable bases than with SMBG,
also avoiding the dependence on the specific sampling design followed by the subject
in collecting his BG measurements.
As said, glucose variability is matter of Chapter 2. The following of this chapter
will provide an overview on the treatment of diabetes, presenting the two major ways
exploited by insulin-treated diabetic subjects to inject exogenous insulin.
1.5 Treatment of diabetes
People with diabetes have to follow specific rules in the management of their lifestyle,
in order to reduce the risk of developing long-term vascular dysfunctions and be able
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to live well with either T1DM or T2DM. The strategy used to treat diabetes has to be
designed by the health care team on an individual basis, and needs to address medical,
physiological, and lifestyle patient-specific issues. Nonetheless, some general basics for
the treatment of the pathology can be outlined, and are defined based on the specific
type of diabetes [7].
In the case of T1DM, the complete lack of insulin production requires the patient to
undergo a strict regimen that typically includes a carefully calculated diet, planned
physical activity, home BG testing a number of times per day, and exogenous insulin
administration through multiple daily insulin injections (Section 1.5.1) or continuous
subcutaneous insulin infusion (Section 1.5.2). In all cases, T1DM patients have to
compensate for the lack of a basal insulin concentration that keeps BG stable through
periods of fasting, and for the missed increase in insulin release after meals. This
requires them to measure their BG before eating, inject a certain amount of insulin
based on the ingested carbohydrates, proteins, and fats, and sample the BG level again
after meal to administer further insulin if needed.
Unlike T1DM, a balanced treatment of T2DM is usually achieved through controlled
diet, exercise, home BG testing, and, in some cases, oral medication and/or insulin.
The prevalence of T2DM people exploiting therapies based on insulin injection is ap-
proximately 40% [7].
1.5.1 Multiple daily insulin injections
In the multiple daily insulin injections therapy, the subject injects a long acting insulin
once or twice a day as a basal dose and has further injections of rapid acting insulin
at each meal time [7]. Insulin is injected through regular syringes or pens, usually at
least four times a day. The speed of action of rapid acting insulin allows people to
administer correction doses between meals if the BG level rises too high.
1.5.2 Continuous subcutaneous insulin infusion
Diabetics treated with continuous subcutaneous insulin infusion use insulin pumps
attached to the their body that deliver constant amounts of rapid or short acting
insulin via a catheter placed under the skin [7]. Insulin pumps are portable devices
that consist of a main pump unit holding an insulin reservoir attached to a long, thin
piece of tubing with a needle or cannula at one end. These computerized devices allow
to release insulin in two ways: in a steady, measured, and continuous dose, to provide
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an appropriate basal insulin concentration, and as a surge dose (called bolus) around
mealtime, to compensate for carbohydrate intake. Because the insulin pump stays
connected to the body, it allows the wearer to modify the amount of insulin he needs
to take by pressing a few buttons at any time of the day, or to program a higher or
lower rate of insulin delivery to occur at a chosen time, e.g., during the night. Around
6% of adults and 19% of children with T1DM use an insulin pump [7]. Insulin pumps
have also recently progressed into the so-called sensor-augmented insulin pumps, where
the insulin pump acts as the receiver of the CGM data sent wirelessly from the sensor
by the transmitter. In both adults and children with inadequately controlled T1DM,
sensor-augmented pump therapy resulted in a significant improvement of HbA1c levels,
as compared with the traditional therapy based on multiple daily insulin injections [29].
1.6 Conclusions
The development of vascular complications from diabetes can be managed and limited
through the achievement of a tight glycemic control based on strict insulin therapy.
Intensive treatment with three or more insulin administrations a day by injection or
insulin pump was shown to lower BG concentration (as monitored by HbA1c levels)
and delay the onset of retinopathy, nephropathy, and neuropathy in insulin-treated
T1DM patients [30]. In the evaluation of the development of diseases from diabetes,
however, not only hyperglycemia but also glycemic fluctuations and swings have to be
considered [31]. Given that, the next chapter will focus on glucose variability, on its
role in the development of complications from diabetes, and on the algorithms available
to quantitatively measure it.

Chapter 2
The role of glucose variability
in diabetes
2.1 The concept of glucose variability
To properly address the issue of developing long-term complications from diabetes,
a sustained high BG level is not the only risk factor that has to be considered, and
the occurrence of abnormal glucose variability (GV) needs to be taken into account as
well. Before considering GV as a relevant element in the assessment of the metabolic
situation of diabetic subjects, the major role in the evaluation of glycemic control
was played by HbA1c, whose levels provide an integrated measure of glycemic expo-
sure during the 2-3 months preceding the examination [32]. In 1993, landmark results
from the Diabetes Control and Complications Trial (DCCT) demonstrated that lower
HbA1c levels achieved in T1DM subjects under intensive insulin treatment led to a
slower progression of diabetic complications with respect to conventionally treated pa-
tients [30]. These findings confirmed the association between hyperglycemia and the
development of vascular diseases from diabetes, establishing HbA1c as the principal in-
dicator of successful therapy and good control, with levels ≤7% deemed appropriate for
reducing the development of diabetic complications [30, 33]. Later investigations made
by the DCCT investigators themselves, however, showed that the risk of retinopathy
progression associated with a given HbA1c level was significantly different between
conventionally and intensively treated patients, suggesting that mean HbA1c could
not be the most complete expression of the degree of glycemia and diabetic complica-
tions might be highly dependent on other factors [31]. Specifically, a greater increase
in the risk of progression to retinopathy over time in participants under conventional
13
14 Chapter 2 The role of glucose variability in diabetes
Figure 2.1 CGM profiles acquired from normal (top panel), T1DM (middle panel),
and T2DM (bottom panel) subjects; black dotted lines at 70 and 180 mg/dL rep-
resent hypo and hyperglycemic thresholds, respectively. These examples are drawn
from the datasets exploited in the study described in Chapter 5, where details about
data collection can be found.
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treatment was found, and this phenomenon was thought to be related to the more
frequent high-amplitude fluctuations experienced by these patients, that might lead
to increased generation of reactive oxygen species and oxidative stress [34, 35]. These
early findings about a significant role of GV in the treatment of diabetes were pro-
gressively supported by a number of other investigations, which together developed a
growing evidence that GV should be regarded as an actual HbA1c-independent risk
factor for the development of long-term vascular complications from diabetes [36–42].
In view of this and of the need of reducing GV in order to achieve desired levels of
glycemic control [43–45], tens of methods to provide an objective evaluation of GV
from BG profiles have been designed. Before detailing some of them in the next sec-
tion, it could be worth providing a qualitative description of the meaning of abnormal
GV by resorting to representative CGM time-series collected from a normal, a T1DM,
and a T2DM subject and reported in Figure 2.1. Abnormal GV typically refers to the
occurrence of repeated high-amplitude glycemic fluctuations and frequent hypo/hyper-
glycemic events, that, as can be seen from Figure 2.1, might be experienced by people
suffering from either type of diabetes. On the other hand, a well-controlled normal
subject usually has his glycemia within the safe euglycemic range, without significant
excursions (see the top panel of Figure 2.1).
2.2 Indices to measure glucose variability
The assessment of GV has been a widely investigated research field, and several in-
dicators to retrospectively quantify GV from SMBG and CGM time-series have been
proposed in the literature. Extensive reviews where all metrics are detailed are avail-
able, e.g., in [44–50]; here, we limit the presentation to 25 indicators that we exploited
in our investigations, detailed in two different subsections to better organize their de-
scription within the text. Among them, some indices are more trivial, like sample mean
and standard deviation (SD) of BG readings, while some others have been specifically
designed for the quantification of GV. In all definitions, the glycemic time-series on
which the index is computed is indicated as {BG(i)}, i = 1, . . . , N , and when present,
Ndays is the duration of the recording in terms of days.
2.2.1 Indices based on the distribution of glycemic levels
This first subsection provides a list of 13 GV indices whose formulations are mostly
derived from the distribution of BG levels and the amplitude of glycemic excursions.
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These metrics are:
– Mean of BG readings (Mean)
Mean =
1
N
N∑
i=1
BG(i) (2.1)
simple and classic indicator mostly influenced by hyperglycemia which shows the
best correlation with HbA1c levels [43, 51, 52];
– SD of BG readings (SD)
SD =
√∑N
i=1 (BG(i)−Mean)2
N
(2.2)
simple statistical method exploited, e.g., in [43, 53, 54], which provides a measure
of variability but is influenced by non-Gaussian distributions and outliers [45];
– Percentage coefficient of variation of BG readings (%CV)
%CV = 100
SD
Mean
(2.3)
variability measure used in statistics which normalizes sample SD to sample mean
and is subject to the same limitations as SD [45];
– Mean over all days of within-day SD of BG readings (SDw)
SDw =
1
Ndays
Ndays∑
j=1
SD(j) (2.4)
with SD(j) being the SD of all measurements collected during the jth day; defined
in [44] and highly correlated with SD [45];
– SD over all days of within-day mean of BG readings (SDdm)
SDdm =
√∑Ndays
j=1 (Mean(j)−MeanAllDays)2
Ndays
(2.5)
with Mean(j) being the mean of all measurements collected during the jth day
and MeanAllDays the average value of Mean(j) over j (that can be different with
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respect to Mean because the number of BG readings per day may vary from a
day to another); as SDw, defined in [44] and correlated with the overall SD [45];
– Median of BG readings (Median)
Median = 50th percentile (2.6)
with Xth percentile being the value below which the X% of observations in a
group of observations fall; simple statistical measure usually more suitable to the
analysis of glycemic time-series than the sample mean because of the skewness
of BG distribution, exploited, e.g., in [53–56];
– Interquartile range of BG readings (IQR)
IQR = 75th percentile− 25th percentile (2.7)
difference between 75th and 25th percentiles, used, e.g., in [53–56];
– Range of BG readings (Range)
Range = max(BG(i))−min(BG(i)) (2.8)
difference between higher and lower BG reading, exploited, e.g., in [45];
– Percentages of BG readings within (%BG in target), below (%BG below target),
and above (%BG above target) the target range 70-180 mg/dL
%BG in target =
# of BG(i) : 70 ≤ BG(i) ≤ 180
N
(2.9)
%BG below target =
# of BG(i) : BG(i) < 70
N
(2.10)
%BG above target =
# of BG(i) : BG(i) > 180
N
(2.11)
indicators used, e.g., in [57–59], simple and direct, but accounting only for the
number of extreme BG fluctuations and not for their amplitude;
– J-index (J-index)
J-index = 0.001 (Mean + SD)2 (2.12)
combination of Mean and SD defined in [60], exploited, e.g., in [45], and shown
to be highly correlated with %BG in target [47];
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– Mean amplitude of glycemic excursions (MAGE)
MAGE =
1
Nexcursions
Nexcursions∑
k=1
∆BG(k) (2.13)
where Nexcursions is the number of glucose excursions having amplitude greater
than one time the SD of the considered segment and ∆BG(k) is the amplitude
of the kth considered excursion; index defined in [61], typically computed for
each day of monitoring and then averaged over all days, and shown to be highly
correlated with the overall SD [45]; an algorithmic implementation of MAGE
for the smart calculation on CGM time-series was provided by Baghurst in [62];
examples of use of this metric can be found in [44, 45].
2.2.2 Indices based on risk and quality of glycemic control
Twelve indices derived from nonlinear transformations of the BG range are presented
in this section. These metrics are:
– MR with R = 100 mg/dL (M100)
M100 =
1
N
N∑
i=1
1000
∣∣∣∣log10(BG(i)100
)∣∣∣∣3 (2.14)
indicator defined in [63, 64] and exploited, e.g., in [45];
– Low blood glucose index (LBGI), high blood glucose index (HBGI), average daily
risk range (ADRR), and blood glucose risk index (BGRI)
These metrics were designed to quantify the risk of hypoglycemia (LBGI), hyper-
glycemia (HBGI), and the overall quality of glycemic control (ADRR and BGRI)
from SMBG time-series. Their formulation was derived from a transformation
of the BG scale detailed by Kovatchev et al. in [65], aimed at symmetrizing the
range of all possible BG values. The reason behind the transformation is the
significantly different size of hypoglycemic (BG<70 mg/dL) and hyperglycemic
(BG>180 mg/dL) ranges, condition that leads to a target BG range (70-180
mg/dL [30]) not centered in the range of all possible BG levels (assuming 20-600
mg/dL), causes the clinical center of the BG range (around 112.5 mg/dL) not to
match the numerical one (around 300 mg/dL), and makes the distribution of BG
measurements skewed and asymmetric. Based on this transformation of the BG
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scale, a BG risk function that assigns a certain degree of risk to each BG reading
was designed and used to subsequently define LBGI and HBGI. Symmetrization
and risk functions are detailed below (Equation 2.15 and 2.16, respectively)
f(BG) = 1.509 ([log(BG)]1.084 − 5.381) (2.15)
r(BG) = 10 f(BG)2 . (2.16)
The effect of the symmetrization function on the original BG range can be im-
mediately drawn from its graphical representation reported in the left panel
of Figure 2.2. The transformation, that makes the BG readings normally dis-
tributed, stretches the hypoglycemic range, shrinks the hyperglycemic range, and
leads to a BG scale symmetric around zero. In the transformed range, thus, the
euglycemic value of 112.5 mg/dL becomes the clinical and numerical center of
the BG scale, and the target BG range results to be centered in the range of
all possible BG values. The BG risk function then defined, shown in the right
panel of Figure 2.2 as plotted against the original BG scale, ranges from 0 to 100,
assigning zero risk to BG readings at 112.5 mg/dL and maximum risk to severe
hypoglycemia (BG around 20 mg/dL) and extreme hyperglycemia (BG around
600 mg/dL).
Figure 2.2 Symmetrization and risk functions proposed by Kovatchev et
al. in [65]. Red lines indicate the clinical center at 112.5 mg/dL and its
transformed value; green lines indicate the target range 70-180 mg/dL and its
transformed value.
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Based on the BG risk function, two further functions were designed. They repre-
sent the risk of low BG (rl(BG)) and high BG (rh(BG)), are specified as follows
rl(BG) =
r(BG), if BG < 112.5 mg/dL0, otherwise (2.17)
rh(BG) =
r(BG), if BG > 112.5 mg/dL0, otherwise (2.18)
and allow the definition of the final LBGI and HBGI [66, 67]
LBGI =
1
N
N∑
i=1
rl(BG) (2.19)
HBGI =
1
N
N∑
i=1
rh(BG) . (2.20)
As far as the indices assessing the overall quality of glycemic control are con-
cerned, the ADRR was defined as the sum of the risk associated to the lower and
higher BG readings of the jth day averaged over all days [68]
ADRR =
1
Ndays
Ndays∑
j=1
[max(rlj(BG)) + max(rhj(BG))] , (2.21)
and the BGRI was designed as the sum of LBGI and HBGI [46]
BGRI = LBGI + HBGI . (2.22)
A description of the clinical relevance of LBGI and HBGI, and of their use in
the literature is discussed in the next chapter.
– Hypoglycemic index (Hypo Index), hyperglycemic index (Hyper Index), and in-
dex of glycemic control (IGC)
Hypo Index, Hyper Index, and IGC are metrics assessing the risk of hypo-
glycemia, hyperglycemia, and the overall quality of glycemic control, as the
previous ones, but are derived from different transformation functions. They
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were introduced by Rodbard in [45] and their formulations are detailed below
Hypo Index =
∑N
i=1 (LLTR− BG(i))b
N × d (2.23)
Hyper Index =
∑N
i=1 (BG(i)− ULTR)a
N × c (2.24)
with IGC being the combination of the previous two
IGC = Hypo Index + Hyper Index (2.25)
and LLTR, ULTR standing for lower and upper limit of target range with default
values at 80 and 140 mg/dL, and a, b, c, and d parameters generally set to 1.1,
2.0, 30, and 30.
– Glycemic risk assessment diabetes equation (GRADE), and percentage contribu-
tions due to euglycemia (%GRADEeu), hypoglycemia (%GRADEhypo), and hy-
perglycemia (%GRADEhyper)
These indicators have been proposed by Hill in [69, 70], and provide a measure
of the quality of glycemic control summarized in the GRADE score, and the
contribution to this score respectively due to euglycemia, hypoglycemia, and hy-
perglycemia. The GRADE score is defined as the average over all BG readings
of the following transformed value
GRADE = 425 (log[log(BG/18)] + 0.16)2 (2.26)
and the three contributions due to the different glycemic conditions are
%GRADEeu = 100
∑
BG in euglycemia GRADE∑
all BG GRADE
(2.27)
%GRADEhypo = 100
∑
BG in hypoglycemia GRADE∑
all BG GRADE
(2.28)
%GRADEhyper = 100
∑
BG in hyperglycemia GRADE∑
all BG GRADE
. (2.29)
Examples of their use and characterization can be found in [45].
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2.3 Open issues and aim of the thesis
The review of techniques for the quantification of GV proposed in the previous sections
provides the state of the art about the assessment of GV in diabetes, and simultane-
ously rises some issues still unsolved within this research field. To give an example,
certain GV indices have been defined and validated only on SMBG profiles, and thus
their use on CGM time-series is not immediate. This is the case, e.g., of LBGI and
HBGI, popular metrics that can be exploited to provide a rapid classification of the
overall quality of a subject’s glucose control if they are computed on SMBG time-
series, but have not a validated physiological meaning when applied to CGM profiles.
Moreover, if we think of all metrics available for GV quantification, we can observe
that the information conveyed by them is highly redundant and a compact way to
describe GV is still missing in the literature. Finally, the exploitation of CGM signals
and GV to classify the metabolic condition of normal and diabetic subjects is a rela-
tively unexplored problem that could deserve an investigation. These three topics are
the object of this dissertation. In particular, in the following chapters we will:
– provide alternate versions of the well-known LBGI and HBGI that are adapted to
the characteristics of CGM time-series, thus allowing to extend the computation
of these risk indices from SMBG to CGM profiles (Chapter 3);
– explore the use of the sparse principal component analysis (SPCA) technique to
provide a parsimonious but still comprehensive description of GV in both T1DM
and T2DM (Chapter 4);
– explore the possibility of using the outputs obtained from SPCA to develop GV-
based classifiers of the quality of glycemic control in T1DM subjects and of the
metabolic condition of normal subjects at risk of developing T2DM, IGT subjects,
and subjects with T2DM diagnosed (Chapter 5).
Chapter 3
Adapting SMBG-based indices to
CGM: the case of LBGI/HBGI 1
3.1 Aim of the investigation
LBGI and HBGI are popular metrics used to quantify the risk of hypo and hyper-
glycemia from sparse SMBG profiles. As discussed in the previous section, they were
designed based on a symmetrization of the BG range [65] to summarize the number
and extent of extreme BG fluctuations into single numbers, with LBGI accounting for
hypoglycemic episodes and HBGI for hyperglycemic ones. Therefore, a higher LBGI
may indicate a large number of mild hypoglycemic events, a small number of severe
hypoglycemic events, or a combination of both, and the same can be said for HBGI
with regard to hyperglycemia.
The clinical relevance of these risk indicators has long been established as LBGI was
shown to predict the occurrence of future severe hypoglycemia (SH) episodes [65, 66]
and HBGI demonstrated a positive correlation with HbA1c levels [65]. Moreover, sig-
nificant cutoff values that allow to promptly classify the quality of the overall glycemic
control of a patient based on his LBGI and HBGI values were also identified [66, 67].
Specifically, the risk of SH can be determined by exploiting LBGI, and is considered
low if LBGI < 2.5, moderate if LBGI is between 2.5 and 5, and high if LBGI > 5, and
the same can be said for HBGI concerning the risk of hyperglycemia, with cutpoints
1The work presented in this chapter was developed under the supervision of Professor Marc Breton
and represents part of the research activity performed during a period of six months spent at the
Center for Diabetes Technology, University of Virginia (Charlottesville, VA, USA).
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identified at HBGI = 4.5 and HBGI = 9.
Because LBGI and HBGI enable a rapid classification of the actual glycemic condi-
tion of a patient, their use in the quantification of GV was largely exploited in the
literature [32, 38, 46, 48, 68, 71–78]. However, using these indicators and their cutoff
values is possible only from SMBG profiles and has never been validated on CGM
data stream. Given the growing use of CGM systems, thus, the aim of this work is
to describe the relationship between SMBG-based and CGM-based LBGI/HBGI, and
provide guidelines to apply when the indices are computed from CGM time-series.
Specifically, based on a dataset of 28 T1DM subjects monitored with both SMBG and
CGM for up to four weeks, we identified transformation functions for LBGI and HBGI
that adapt these indicators to the characteristics of CGM profiles and enable references
to previous works and clinically relevant thresholds [79].
3.2 Dataset
3.2.1 Data collection
Data used in this work were collected at the University of Virginia (Charlottesville,
VA, USA) and are baseline data from a study aimed at investigating how BG changes
in response to insulin and what the body does to counteract low BG in people with
T1DM. Twenty-eight T1DM subjects were involved in the analysis. All subjects were
under insulin pump therapy, and monitored for up to four weeks with both SMBG
and CGM systems. After two weeks, they received a liquid mixed-meal in an inpatient
setting, and had their BG monitored in order to study insulin sensitivity; then, they
received additional insulin injections to cause a condition of low BG, to understand
how the body responds to hypoglycemia. All subjects were closely monitored during
the time insulin was given, by frequent checks of BG and constant medical and nursing
supervision. Beyond the inpatient day, subjects were in daily-life conditions. During
the study, participants were asked to use their own insulin pump and glucometer,
and the same glucometer had to be used for the entire study. CGM profiles were
collected using the DexCom R© G4 R© glucose sensor [22]. Demographic characteristics
of the subjects expressed as mean±SD were age 43±11 years, duration of diabetes
23±11 years, duration of pump therapy 11±7 years, and HbA1c 8±1%. The study
was approved by the local ethical committee and registered at ClinicalTrials.Gov with
the identifier number NCT01835964.
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3.2.2 Data preprocessing and characterization
To avoid any influence of the results on the protocol used for data collection, the
inpatient day was removed from SMBG and CGM profiles. Days where sensor issues
occurred and no CGM points were stored were removed also from the SMBG time-
series. Beyond this, all datapoints collected were kept in the study. The subject
storing the little number of SMBG samples had an SMBG profile of 2.61 points/day
on average with 73 measurements acquired over the entire four weeks. The longest
profile was made up of 315 datapoints, with 11.25 points/day on average. Mean value
over the whole population of the average length per day was 5.65 samples and of
the entire length was 158.26. CGM data were collected with a sampling time of five
minutes. Figure 3.1 shows an example of data collected from a representative subject;
Figure 3.2 shows histograms of the distribution of SMBG and CGM datapoints across
the time of the day, where it can be seen that CGM data are acquired almost constantly
throughout the day, while SMBGs are mostly acquired around meal times.
3.3 Design of the strategy to correct LBGI/HBGI
The relationship between CGM-based and SMBG-based LBGI/HBGI was described
using linear and nonlinear models. The acceptance/rejection of a model was made
through the assessment of the obtained fit, statistical significance of parameter esti-
mates, residuals, QQ-plot of residuals, and performances in terms of classification of
the subjects’ risk of hypo/hyperglycemia as compared to the SMBG-based one.
Defining the index computed on CGM as the independent variable or predictor (x) and
that computed on SMBG as the dependent one (y), the linear model was the canonical
straight line described as
y = mx+ q . (3.1)
When a liner description was not satisfactory to match CGM-based and SMBG-based
LBGI/HBGI, the following three-parameter nonlinear model was considered
y = ax+ b− 1
c+ x
. (3.2)
The number of model parameters in 3.2 was also reduced by imposing the reasonable
constraint of having a curve meeting the origin of the Cartesian coordinate system.
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Figure 3.1 Example of data used to tune the LBGI/HBGI transformation func-
tions. SMBG and CGM data are shown as red triangles and blue profile, respectively;
pink lines identify the four week of monitoring; black line is at noon of the inpatient
day.
Figure 3.2 Distribution of SMBG (top panel) and CGM (bottom panel) data-
points across the day. Values were obtained as average over all days for each subject,
and then average over all subjects.
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This led to the following two-parameter formulation
y = ax+ b− 1
b+ x
. (3.3)
Models were identified on the available data using the least squares estimator.
3.4 CGM-adapted risk indices
3.4.1 HBGI for CGM
The linear model detailed by Equation 3.1 was used to describe the relationship be-
tween SMBG-based and CGM-based HBGI. Fit, residuals, and QQ-plot of residuals
are shown in Figure 3.3, upper, lower-left, and lower-right panel, respectively; results
from model identification are summarized in the upper rows of Table 3.1. The table
shows the estimates of parameters, their precision expressed as standard error (SE),
t statistics for testing the null hypothesis that parameters are zero, and p-values as-
sociated with t statistics. A p-value lower than 0.05 was considered to be statistically
significant and allowed the rejection of the null hypothesis. As apparent from the top
panel of Figure 3.3, fit is extremely satisfactory; the mean squared error (MSE) for
this model was equal to 6.2 and a value of 75% was obtained for the coefficient of de-
termination (R2), revealing that the model can account for 75% of the variance of the
original SMBG-based HBGI values. Looking at residuals, they appear sufficiently un-
correlated and, except from some outliers probably related to biasing SMBG sampling
designs, QQ-plot suggests to consider them as drawn from a normal distribution. The
last column of Table 3.1, however, shows that the p-value associated with q is much
greater than 0.05, indicating that the parameter is not statistically significant within
the model. Because of this finding, a linear model with slope and intercept forced
to zero was then identified on the experimental data. Fit, residuals, and QQ-plot of
residuals are shown in Figure 3.4, upper, lower-left, and lower-right panel, respectively,
and results are summarized in the lower rows of Table 3.1. Fit and residuals are as
satisfactory as for the previous model, with MSE equal to 6, and the obtained estimate
for m is extremely close to one, suggesting the possibility of using no transformation
to compute HBGI from CGM time-series.
To assess the reliability of this result, the CGM-based classification of the patients’
risk of hyperglycemia was compared with the gold-standard SMBG-based one. Table
3.2 shows how subjects were assigned to the different risk classes in the two cases (left
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Figure 3.3 Model prediction (red line) and experimental data points (blue circles)
for HBGI correction as described with a full linear model (upper panel), together
with residuals (lower-left panel) and their QQ-plot (lower-right panel).
Figure 3.4 Model prediction (red line) and experimental data points (blue circles)
for HBGI correction as described with a linear model with slope and intercept forced
to zero (upper panel), together with residuals (lower-left panel) and their QQ-plot
(lower-right panel).
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columns), and what kind of errors were computed in the CGM-based classification
(right columns). These results are satisfactory not only because 82% of patients were
classified correctly, but also observing that misclassification was of only one class (no
subject at low risk was classified at high risk, and vice versa) and extremely balanced
in over and underestimation. This suggests that there is no systematic error that
needs to be corrected, and classification errors are random and most likely linked to
the potentially biasing designs used to collect SMBG readings and/or to possible mis-
calibration of the sensors.
Given these results, the one-parameter linear model was considered reliable to describe
the relationship between SMBG-based and CGM-based HBGI, and we could conclude
that HBGI as derived from CGM is interchangeable with SMBG-based HBGI.
HBGI
Linear model with slope and intercept
estimate SE t p-value
m 1.0436 0.1182 8.8319 2.6354 · 10−9
q -0.0619 1.0451 -0.0593 0.9532
Linear model with slope (intercept forced to zero)
estimate SE t p-value
m 1.0374 0.0523 19.8356 3.2566 · 10−17
q 0 – – –
Table 3.1 Results from the identification of a linear model with and without in-
tercept for the correction of HBGI.
low
risk
moderate
risk
high
risk
underest
errors
UNDEREST
errors
overest
errors
OVEREST
errors
SMBG based classification
8 9 11 – – – –
CGM based classification
7 11 10 3 0 2 0
Table 3.2 Classification of the risk of hyperglycemia as assessed by HBGI com-
puted on SMBG and CGM. On the left side of the table, subjects assigned to each
risk group are reported; on the right side of the table, under and overestimation
errors due to the assessment of HBGI on CGM are listed (underest/overest errors
stand for misclassification of one class; UNDEREST/OVEREST errors stand for
misclassification of two classes).
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3.4.2 LBGI for CGM
The first model identified on SMBG-based LBGI values was the linear one (Equation
3.1), that provided parameter estimates summarized in the upper rows of Table 3.3.
Along with parameter values, as for HBGI, Table 3.3 shows their precision expressed
in terms of SE, t statistics to test the null hypothesis that parameters are equal to
zero, and p-values to be considered in accepting or rejecting that hypothesis. For the
linear model, both parameters were statistically significant, MSE of 0.68 was obtained,
and R2 resulted equal to 76%. However, despite acceptable residuals (lower-left and
lower-right panel of Figure 3.5) it appears clear that a straight line cannot provide a
reliable description of the relationship between SMBG-based and CGM-based LBGI at
lowest LBGI values (upper panel of Figure 3.5). We, thus, moved to the identification
of the nonlinear model 3.3. Parameter estimates obtained in this case are reported in
the lower rows of Table 3.3; the prediction is plotted against experimental data in the
upper panel of Figure 3.6, and residuals and QQ-plot are shown in the lower-left and
lower-right panel of Figure 3.6, respectively. Again both parameters were statistically
significant and estimated with good precision. The MSE obtained for this model was
equal to 0.62, and residuals are satisfactory. Nonetheless, in choosing the best model
to be used to transform CGM-based LBGI, it is worth observing that the nonlinear
model shows better performance than the linear one only at very low LBGI values,
where there is no significant glycemic risk and a lower degree of precision in describing
the data could be still adequate.
To assess the actual need for a correction and to investigate if the nonlinear model could
make any significant difference, the comparison of the classification of subjects’ risk
of hypoglycemia was performed as done for HBGI. Table 3.4 shows the assignment
of subjects to the corresponding risk group based on LBGI computed from SMBG,
CGM, linearly corrected CGM, and nonlinearly corrected CGM. We can observe from
the table that the application of the linear transformation to correct the CGM-based
LBGI values dramatically changed the assessment of the risk of hypoglycemia, with
classification performances largely improved after the correction. Errors in identifying
the risk zone decreased from 7 to 5 (with 82% of subjects correctly classified), became
random and balanced in over and underestimation, and the two-class error performed
without correcting LBGI was avoided. The same results were obtained applying the
nonlinear transformation to CGM-based LBGI values.
From this analysis, we can conclude that the computation of LBGI from CGM time-
series is biased, with a clear underestimation of the actual risk of hypoglycemia, and
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Figure 3.5 Model prediction (red line) and experimental data points (blue circles)
for LBGI correction as described with a full linear model (upper panel), together
with residuals (lower-left panel) and their QQ-plot (lower-right panel).
Figure 3.6 Model prediction (red line) and experimental data points (blue circles)
for LBGI correction as described with a nonlinear model (upper panel), together with
residuals (lower-left panel) and their QQ-plot (lower-right panel).
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a correction is needed. Though the nonlinear transformation is more accurate at low
LBGI values, no advantage was visible in terms of classification. As already mentioned,
this is due to the fact that the nonlinear model works better in a very low risk zone,
where a high degree of precision is not needed. Given that, the linear model can be
considered satisfactory in describing the relationship between SMBG-based and CGM-
based LBGI, turning out to be the transformation function that better adapts LBGI
to the characteristics of CGM signals.
LBGI
Linear model with slope and intercept
estimate SE t p-value
m 1.0199 0.1125 9.0661 1.5674 · 10−9
q 0.6521 0.2519 2.5893 0.0156
Nonlinear model without saturation
estimate SE t p-value
a 0.8346 0.1284 6.5026 6.8204 · 10−7
b 0.6476 0.1412 4.5876 1.1107 · 10−5
Table 3.3 Results from the identification of a linear model with intercept and a
nonlinear model without saturation for the correction of LBGI.
low
risk
moderate
risk
high
risk
underest
errors
UNDEREST
errors
overest
errors
OVEREST
errors
SMBG based classification
8 9 11 – – – –
CGM based classification
23 4 1 6 1 0 0
LINEARLY corrected CGM based classification
16 9 3 2 0 3 0
NONLINEARLY corrected CGM based classification
16 9 3 2 0 3 0
Table 3.4 Classification of the risk of hypoglycemia as assessed by LBGI com-
puted on SMBG and CGM. On the left side of the table, subjects assigned to each
risk group are reported; on the right side of the table, under and overestimation
errors due to the assessment of LBGI on CGM are listed (underest/overest errors
stand for misclassification of one class; UNDEREST/OVEREST errors stand for
misclassification of two classes). On the bottom of the table, we can observe the
performance obtained when LBGI from CGM was conveniently corrected.
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3.5 Conclusions
The risk of hypo and hyperglycemia can be assessed in a straightforward way by
computing LBGI and HBGI on collections of SMBG readings. These indicators have
been shown to be predictive of future glycemic events (e.g., LBGI of the frequency of
future SH episodes) and clinically relevant cutoff values have been defined to classify
the current condition of a patient based on his SMBG-based LBGI/HBGI. Because of
their easy and fast implementation and immediate interpretation, LBGI and HBGI are
powerful tools to assess glycemic variability and risks, and their applicability to CGM
signals could be of significant impact both from a scientific and a clinical viewpoint.
The aim of this study was, thus, defining alternate versions of LBGI and HBGI that
fit better the characteristics of CGMs, providing transformations to apply when these
indices are computed from CGM time-series and enabling references to previously
published works and relevant cutoff values.
In doing that, a number of models were exploited to describe the relationship between
SMBG-based and CGM-based LBGI/HBGI, and the optimal parameters to correct the
indicators were identified. It is worth mentioning that, however, transformations and
correction coefficients of LBGI/HBGI do not account only for the different sampling
rate of SMBG and CGM systems, but also for some intrinsic characteristics of the
specific sensor used for the continuous monitoring of glucose levels. This means that
studies developed on data acquired with a CGM device different from the DexCom R©
G4 R© could provide additional information as to the optimal correction of LBGI and
HBGI. Thus, further work shall consider the correction coefficients from a wider range
of CGM systems and the potential need for a sensor-specific correction.
Beyond this, other analyses to systematically assess the influence of the sampling
frequency on LBGI/HBGI values are worth to be computed. Simulation studies could
be used to recreate CGM time-series and randomly downsample them up to recreating a
full seven-point SMBG profile, with the aim of identifying the maximum number of BG
samples that allows references to previous works without correction coefficients. Also,
the effect of a significant decrease of the number of SMBGs should be investigated, to
provide an inferior limit to be respected in order to obtain physiologically meaningful
values of LBGI and HBGI. As an additional variable to be considered in all cases, the
effect of the placement of SMBG samples across the day is likely to have a significant
influence on the values obtained for LBGI and HBGI, and defining an optimal scenario
for SMBG measurements could be really interesting and useful to get a uniformity, e.g.,
in clinical trials. These open issues will be matter of future works.

Chapter 4
Parsimonious description of
glucose variability by SPCA
4.1 Aim of the investigation
As outlined in Chapter 2, a number of indicators for GV quantification have been
proposed in the literature [43, 44, 46–50]. These metrics include indices derived from
the distribution of glucose readings and the amplitude of glycemic excursions, mea-
sures of the risk of hyper and hypoglycemia, and indicators of the overall quality of
glycemic control. The issue with the large pool of defined GV metrics, however, is that
a gold-standard technique to assess GV has not been identified yet, the information
carried by the indices is highly redundant, and some indicators may be of relatively
minor added value in the characterization of GV within a diabetic population.
To manage this situation, we propose the use of SPCA, a technique introduced by Zou
and co-workers in 2006 [80] that allows to extract a small combination of GV indices
which preserves a large part of the variance originally conveyed by a wider pool of
indicators. Based on this method, we can select a reduced subset of metrics that are
able to effectively characterize the whole GV of a diabetic population, and thus we
end up providing a parsimonious description of GV in diabetes.
In our investigation, SPCA was applied to the 25 GV indices introduced in the previ-
ous chapter, evaluated on two T1DM CGM datasets made up of 17 and 16 time-series,
respectively, and on the one obtained by merging them. The dependency of the ex-
tracted GV indices from the specific T1DM dataset was assessed, and the application
of the technique was then extended to a 13 CGM time-series T2DM dataset.
The applicability of LBGI and HBGI to CGM time-series was possible thanks to the
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transformation functions previously described [79].
In the following of this chapter, Section 4.2 describes the SPCA technique, Section
4.3 provides details about data collection, and Sections 4.4 and 4.5 present the results
obtained from the application of SPCA to T1DM [81] and T2DM [82], respectively,
discussing the choice of parameters needed for the implementation of the technique.
4.2 SPCA
SPCA is a two-step data processing technique of general applicability introduced by
Zou et al. in [80]. In our implementation, assuming that the n observations of the m
GV metrics are stored along the columns of the n×m matrix X, the two steps are:
A. apply the canonical principal component analysis (PCA) [83] to the matrix X to
retrieve the principal components (PCs), and select a reduced number p (p m)
of them, saving the majority of the total original variance;
B. since PCs are linear combinations (regressions) of all GV indices and have not
a direct physiological meaning, apply the least absolute shrinkage and selection
operator (LASSO) constraint to each selected PC, to obtain sparse estimates of
regression coefficients and maintain in the PC regressor a reduced number of
metrics (those forming the parsimonious set of indices to describe GV).
Before entering SPCA, a normalization of the indices within each dataset was per-
formed. Specifically, the indices were mean centered and scaled (i.e., divided by their
sample SD), and this preprocessing allowed us to avoid any bias in the SPCA results
and compare the outputs obtained from the application of SPCA to different datasets
(the importance of this normalization is discussed in the Appendix to our paper [81]).
To have a quick overview of the implementation of SPCA in our problem, a block
diagram highlighting the main steps of the procedure is shown in Figure 4.1.
Calculation of GV indices and implementation of SPCA were performed with software
developed by us in MATLAB R© R2012a.
A. PCA and formulation of the regression problem
Let the covariance matrix of the data X be a general full matrix (i.e., the m variables
are correlated among them). Then, the aim of PCA is to find a linear transformation
Y = X S (4.1)
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that allows to reduce the correlation of the original data. Formally, we are seeking for
an orthogonal matrix S to transform the original data X into the new data Y, under
the constraint that the covariance matrix of Y is a diagonal matrix.
To solve the problem and find the transformation matrix S, PCA resorts to the singular
value decomposition of the data matrix, that allows to express X as
X = U Σ VT (4.2)
with U being an n×n orthogonal matrix collecting the vectors ui = Xvi/σi, Σ an n×m
rectangular diagonal matrix with nonnegative diagonal entries σi =
√
λi, known as
singular values, and V an m×m orthogonal matrix whose columns are the eigenvectors
of the matrix XT X, with associated eigenvalues λi. Given the orthogonality of V,
Equation 4.2 can be rewritten as
X V = U Σ (4.3)
and from this statement it is straightforward to see that the transformation matrix S
we are looking for is exactly the matrix V collecting the eigenvectors of XT X. As
requested by the algorithm, in fact, V is orthogonal, and the new data expressed as
U Σ have a diagonal covariance matrix (because U is orthogonal and Σ is diagonal).
Being S = V, the transformed data collected in the n×m matrix Y can be written as
Y = X V (4.4)
where the columns of Y are m new uncorrelated variables known as PCs of X.
The main advantages of data decomposition through PCA is that PCs capture the
maximum variability among the columns of X [80] and are sorted in decreasing order
in terms of explained variance of the original data (i.e., the first greatest variance is
explained by the first PC, the second greatest variance by the second PC, and so on);
furthermore, PCs are uncorrelated and thus can be considered separately one from
another. Typically, the application of PCA leads to the selection of p PCs, and data
dimensionality can be reduced from m to p m, with minimum loss of information.
Looking specifically at PCs, they are obtained as linear combinations of all the m
initial variables, with nonzero coefficients (also called loadings, and referred to as α
(i)
j
in Figure 4.1) collected along the columns of the matrix V. Denoting now V = B, the
problem of searching for the unknown loading matrix B can be seen as a regression
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Figure 4.1 Schematic representation of the implementation of SPCA in our prob-
lem. The block diagram highlights the need of two user parameters, i.e., the number
of PCs selected after PCA and the number of predictors kept in the regressors by
the LASSO constraint. Also, inputs and outputs of each step are detailed.
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problem. In particular, the ith column of Y can be written as
yi = X β (4.5)
and each column vector β of the loading matrix B can be estimated from the data yi
using the LASSO constraint.
B. LASSO estimation of sparse loadings
As just seen, PCA allows to reduce data dimensionality through the selection of p
uncorrelated PCs. Each PC, however, results from a linear combination of all the orig-
inal variables with coefficients α
(i)
j that are typically nonzero. The aim of the LASSO
estimation is to reduce the number of explicitly used variables, through the calculation
of sparse loadings. Defining β̂
LASSO
the estimated vector of sparse coefficients, it is
obtained from the solution of the following optimization problem
β̂
LASSO
= argmin
β
∣∣∣∣∣
∣∣∣∣∣yi −
m∑
j=1
Xi βj
∣∣∣∣∣
∣∣∣∣∣
2
+ λ
m∑
j=1
|βj|
 (4.6)
where Xj is the j
th column of the data matrix X collecting the n observations of the
same variable. As one can see from Equation 4.6, the cost function here defined is made
up of two different terms, i.e., the residual sum of squares and the sum of coefficient
absolute values; the role of each term within the optimization problem is determined
by the nonnegative parameter λ. Specifically, high values of λ lead to a large number
of coefficients shrunk to zero and a small number of variables kept in the PC regressor,
while λ values close to zero lead to a full estimated loading vector. In practice, λ is
set based on the requirements of the considered problem, and, once specified, if large
enough, allows to select a reduced number of variables from the larger initial pool;
the ensemble of the selected variables is usually able to preserve a great part of the
variance originally explained by the whole set of metrics.
4.3 Datasets
T1DM data considered for the analysis are two CGM datasets collected within the EU
FP7 project Diadvisor (2008-2012) [84] using the Dexcom R© SEVEN R© Plus CGM Sys-
tem (Dexcom, San Diego, CA, USA) [22]. In this work, dataset 1 is made up of CGM
time-series acquired from 17 T1DM males studied at the Department of Medicine,
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University of Padova (Padova, Italy), while dataset 2 comprises 16 T1DM CGM pro-
files collected at the Department of Endocrinology, Diabetes, Nutrition, University of
Montpellier (Montpellier, France). A third dataset of 33 CGM time-series obtained by
combining datasets 1 and 2 was also considered in the analysis.
The T2DM CGM dataset, on the other hand, is made up of CGM time-series col-
lected from 13 males under normal life conditions using the Medtronic R© Guardian
REAL-Time R© CGM System (Medtronic, Northridge, CA) [85]. Mean±SD demo-
graphic characteristics of the subjects are age 54.4±10.0 years, duration of diabetes
10.7±7.0 years, HbA1c 7.4±1.4 %, and BMI 29.4±3.6 kg/m2. Data have been collected
within the ongoing EU FP7 project MOSAIC [86].
4.4 Parsimonious set of indices in T1DM
The application of SPCA to T1DM involved the assessment of the technique on two
different CGM datasets, and on the one obtained by merging them. We provide results
obtained in the three scenarios, discuss the choice of the two SPCA parameters (i.e.,
the number of selected PCs and the number of GV indices kept in the regressor), and
compare the parsimonious sets of indicators finally extracted by SPCA.
The first T1DM dataset we considered in the study was made up of n = 17 CGM
profiles. The m = 25 GV indices were assessed on the time-series, normalized, and
the n × m data matrix X was built up. To determine the number of PCs selected
after the application of PCA to X, a threshold was set in terms of explained variance;
then, the number of selected PCs could be increased by one if the gained explained
variance was large enough. In particular, 85% of the variance of the original data was
set as minimum value to be preserved, and an additional PC was selected only if the
increase of explained variance was at least of 10%. The reason of such a choice, which
is somewhat arbitrary, is that 85% of the initial variance is a sufficiently large value to
be saved, and a relevant benefit has to derive from the further increase of the number
of PCs (since it implies an increased number of finally selected GV indices). As far
as dataset 1 is concerned, a plot of the percentage explained variance as a function of
the number of selected PCs is reported in the top-left panel of Figure 4.2. It is easy
to appreciate from it that, to explain at least 85% of the variance originally present
in the data, two PCs were necessary; this number of PCs was also sufficient, since
passing from two to three PCs, less than 6% of explained variance was gained. For
these reasons, p = 2 PCs were finally selected for dataset 1, saving 87% of the vari-
ance originally present in the data. The PCA step, thus, enabled to achieve a great
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reduction in data dimensionality (from m = 25 to p = 2) with a minimum loss of
information. As described in Section 4.2, however, each PC was obtained as a linear
combination of all GV indices. Then, to reduce the number of variables contributing
to the regression, the LASSO estimation of sparse loadings was computed for each PC,
setting to five the maximum number of nonzero coefficients; the GV indices selected
by SPCA were those corresponding to nonzero loadings. The number of nonzero coef-
ficients, and thus of selected GV metrics for each PC, was the second input required
to the user. Again, a certain degree of subjectivity is involved in the choice. In the
present study, we wanted to have the same number of selected GV indices per PC for
both datasets, and we decided to set it as the smallest number of variables that allowed
to explain at least 60% of the initial variance in both datasets. In Figure 4.2, top and
middle right panels, the percentage explained variance is plotted against the number
of selected GV indices per PC, for the previously determined number of selected PCs.
As the reader can appreciate from the inspection of top-right (dataset 1) and middle-
right (dataset 2) panels, the minimum number of GV metrics that allowed to preserve
at least 60% of the original variance in both cases was equal to five. Thus, five was
the chosen number of nonzero loadings per PC. Of note is that imposing a maximum
number of nonzero coefficients is the same as setting a certain value for the parameter
λ. Specifically, there exist a number of λ values that satisfy the requirement of having
not more than five loadings different from zero; between them, we chose the smallest
one, as it represents the first solution to the optimization problem. For dataset 1, with
five (out of 25) GV indices for each of the two (out of 25) PCs, SPCA finally allowed
to explain 77% of the variance originally explained by the whole pool of GV indices.
The selected metrics are, thus, sufficient for a comprehensive characterization of GV
in the analyzed population of 17 T1DM subjects. Results obtained from dataset 1 are
summarized in Table 4.1 (top panel), where the indices selected for each PC are listed.
Moving on to the second dataset, the data matrix X was made up of n = 16 rows
and again m = 25 columns, and the choice of SPCA parameters was developed as
described for dataset 1. Again, two PCs turned out to be sufficient to explain most
of the variance of the initial data, with 86% of the original variance saved, and the
LASSO constraint allowed to select five metrics for each of the two PCs. With five
indices for each PC, SPCA finally explained 61% of the variance originally conveyed
by the 25 considered GV indices. Results obtained from this dataset are summarized
in the middle panel of Table 4.1, and plots of the percentage explained variance as
a function of SPCA parameters are shown in the middle panels of Figure 4.2, below
those referred to dataset 1.
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Figure 4.2 Plots of the explained variance (%) vs the number of selected PCs
(left panels) and, for the chosen number of PCs (i.e., 2), vs the number of selected
GV metrics (right panels) in T1DM. Top panels refer to dataset 1, middle panels to
dataset 2, and bottom panels to dataset 1+2. Thresholds fixed by the user are also
shown as red horizontal lines at 85% for left panels and 60% for right ones.
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T1DM dataset 1 (77%)
First PC Second PC
J-index %CV
MAGE Range
ADRR LBGI
IGC ADRR
%GRADEeu Hypo Index
T1DM dataset 2 (61%)
First PC Second PC
SD %CV
BGRI Median
IGC %BG below target
%GRADEeu %BG above target
– LBGI
T1DM dataset 1+2 (62%)
First PC Second PC
J-index %CV
ADRR Median
BGRI %BG above target
IGC LBGI
%GRADEeu %GRADEhypo
Table 4.1 GV indices selected by SPCA for each PC for the T1DM datasets (1 -
top, 2 - middle, and 1+2 - bottom).
Results obtained so far allow us to make some observations and remarks.
Focusing on the first step of the algorithm, the application of PCA to GV indices
showed that two out of 25 PCs are sufficient to preserve more than 85% of the total
variance originally present in the data. This means that, if analyzed in terms of PCs,
GV is mainly a two-dimensional phenomenon. Moreover, the LASSO step confirmed
that a subset of up to five metrics extracted for each of the two PCs was enough
to save a still large percentage of the original variance (77% in dataset 1 and 61% in
dataset 2), suggesting that the two dimensions that well describe GV can be effectively
characterized by five predictors each, instead of 25.
Regarding specifically the obtained subsets of metrics in the two datasets, we can
observe that most of the selected GV indices result to be measures related to the
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dispersion of glucose distribution (e.g., SD, %CV, and J-index), the overall quality
of glycemic control (e.g., ADRR, BGRI, and IGC), and the hypoglycemic state (e.g.,
LBGI, Hypo Index, %BG below target, and %GRADEhypo), and it may happen that
two indicators well correlated are selected within the same PC. This is the case, e.g.,
of LBGI and Hypo Index in dataset 1, and BGRI and IGC in dataset 2. To prove that,
even if correlated, both indicators selected by SPCA in the two scenarios are effectively
necessary to explain the final percentage of the original variance, we removed LBGI
from the selected indices in dataset 1 while maintaining Hypo Index, and removed
BGRI in dataset 2, while keeping IGC. In the first case, the percentage explained vari-
ance decreased from 77% to 64%; in the second case, it decreased from 61% to 28%.
This confirms that even if two indices are well correlated and seem to measure almost
the same entity, both of them may be necessary to explain a large percentage of the
variance of the original data.
In addition to identifying the parsimonious set of GV indices for each dataset, it is
worthwhile investigating how many and which indices are selected in all cases, thus
seeming able to well characterize GV in T1DM, independently from the specific dataset.
In particular, referring the reader to Table 4.1 where all the obtained results are sum-
marized, we can observe that, for the first PC, two selected GV indices are shared by
both datasets 1 and 2. These metrics are IGC and %GRADEeu. On the other hand,
J-index, MAGE, and ADRR extracted for dataset 1 are replaced by SD and BGRI in
dataset 2. As far as the second PC is concerned, again two GV indices are in common
to datasets 1 and 2 (i.e., %CV and LBGI), while Range, ADRR, and Hypo Index,
selected for dataset 1, are substituted by Median and %BG below/above target in
dataset 2. Considering specifically the pool of GV metrics shared by the two datasets,
thus, it comprises GV metrics (i.e., IGC, %GRADEeu, %CV, and LBGI) that evaluate
the overall quality of glycemic control (IGC), the euglycemic state (%GRADEeu), the
dispersion of glucose distribution (%CV), and the hypoglycemic state (LBGI). From
our results, this pool of four GV indices appears independent from the specific T1DM
dataset and could be regarded as particularly representative of GV in T1DM. However,
it is important to stress that there is still no evidence of this result, since more datasets,
comprising a larger number of subjects, are needed to investigate the determination of
the most representative subset of GV indices in T1DM on more solid grounds.
As said before, SPCA was also applied to the dataset obtained by merging datasets
1 and 2. Dataset 1+2 was made up of 33 CGM time-series, and the application of
SPCA to it followed the same strategy used for the previous scenarios, selecting two
PCs and saving five GV indices for each of them. As expected, two PCs were able to
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explain more than 85% of the initial variance (in particular, 86% was saved) and five
nonzero loadings for each PC allowed finally to preserve 62% of the variance originally
conveyed by all metrics. The parsimonious set of indices for dataset 1+2 is reported
in the bottom panel of Table 4.1, and plots of the explained variance vs SPCA param-
eters are shown in the bottom panels of Figure 4.2. Looking at the parsimonious set
of indicators, it is possible to see that the four indices shared by datasets 1 and 2 were
selected for dataset 1+2 as well, as expected from a T1DM dataset.
4.5 Parsimonious set of indices in T2DM
Results described in the previous section demonstrate that SPCA is a valuable tool to
provide a parsimonious but still comprehensive description of GV in T1DM, selecting
a small subset of up to 10 indicators and saving more than 60% of the original vari-
ance conveyed by 25 GV indices. Moreover, our analyses showed that a small group of
four metrics (i.e., IGC, %GRADEeu, %CV, and LBGI) is shared by all the considered
T1DM datasets, suggesting the existence of a subset of indicators particularly repre-
sentative of GV in T1DM regardless of the specific considered dataset. Given these
findings, we thought that extending the technique to T2DM could be an interesting
investigation, to further confirm the capability of SPCA to parsimoniously describe
GV and to assess whether any selected metric was shared by the two types of diabetes.
As done in T1DM, the m = 25 GV indices were evaluated on the n = 13 CGM profiles
of the T2DM dataset, and SPCA was applied to the data matrix X built up after
the normalization of the indices. The first step of SPCA led again to the selection of
two out of 25 PCs, since with two PCs it was possible to go beyond the fixed 85%
threshold (see the left panel of Figure 4.3) and save 88% of the original variance. The
LASSO step was then performed, and the trend of the percentage explained variance
as a function of the number of GV indices selected per PC is shown in the right panel
of Figure 4.3. From the plot, it can be seen that with a pool of indices of the same
dimension as that selected for the T1DM datasets, i.e., made up of 10 metrics, the
variance finally saved for the T2DM dataset was equal to 83% of the total original one.
To cross the 60% threshold of explained variance for this specific dataset, on the other
hand, an even smaller subset of indices was sufficient. In particular, selecting two GV
indices for each of the two PCs, 67% of the original variance was explained, suggesting
that T2DM may need a lower number of indicators than T1DM to explain the same
percentage of the original variance (to confirm the last speculation, however, other
T2DM datasets have to be analyzed). The parsimonious set of GV indices selected by
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SPCA for the T2DM dataset is reported in Table 4.2. The table shows the 10-index
pool (five indices for each PC), and the smaller group of four metrics, that is a subset
of the former, is made up of the indicators reported as underlined.
Figure 4.3 Plots of the explained variance (%) vs the number of selected PCs (left
panels) and, for the chosen number of PCs (i.e., 2), vs the number of selected GV
metrics (right panels) in T2DM. Thresholds fixed by the user are also shown as red
horizontal lines at 85% for left panels and 60% for right ones.
T2DM dataset (83%)
First PC Second PC
J-index %CV
ADRR Median
BGRI %BG below target
%GRADEeu LBGI
%GRADEhyper Hypo Index
Table 4.2 GV indices selected by SPCA for each PC for the T2DM dataset.
What is of course possible to state from these results is that SPCA confirms its ca-
pability to parsimoniously describe GV in diabetes. Then, we can see that the subset
of four indicators shared by all the T1DM datasets is largely shared by the T2DM
dataset too. Three out of four indicators (i.e., %GRADEeu, %CV, and LBGI), in fact,
belong to the T2DM parsimonious set of indices, and this finding could suggest that
these metrics are particularly informative of GV in diabetes, regardless of the specific
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type of disease. As said before, however, this result needs to be confirmed by a larger
number of datasets.
4.6 Conclusions
GV is believed to be a risk factor for the development of long-term complications from
diabetes, and tens of different indicators for its quantification from SMBG and CGM
profiles have been proposed in the literature. The issue with the quantification of GV,
however, is that a gold-standard approach for its evaluation has not been identified
yet, and, even if a combination of indices is probably necessary to well describe GV
[87, 88], some indicators can provide redundant information and can be of relatively
minor added value in the characterization of GV within a diabetic population.
To identify a reduced subset of indicators that can provide a parsimonious but still
comprehensive description of GV in diabetes, we proposed the use of a technique known
in the literature as SPCA. If applied to a pool of GV indices evaluated on a dataset
of glycemic profiles, SPCA allows to determine a subset of indicators able to explain
a large part of the variance originally revealed by the whole pool of metrics. In other
terms, SPCA allows the identification of a combination of a reduced number of indices
that is still effective for describing the variance of a larger pool of GV indicators within
the considered group of subjects.
The use of SPCA was assessed on both T1DM [81] and T2DM [82] CGM datasets, and
the obtained results confirmed its usability as a tool to parsimoniously describe GV.
Also, our findings showed that this technique can be exploited to determine a small
subset of indicators particularly representative of GV in the overall diabetes, given
that some indicators emerged to be selected in all scenarios, regardless of the specific
dataset or type of disease.
To use SPCA as a tool to identify the gold-standard combination of indicators to quan-
tify GV, however, a larger number of CGM datasets need to be considered, so that the
whole diabetic population could be represented and the final parsimonious set of GV
metrics can be identified. In addition, we need also to observe that the number of avail-
able CGM time-series determines the ratio between number of observations (n) and
number of variables (m) used to build the data matrix X. An insufficiently high ratio
can result in high dimension low sample size problems, with potential inconsistency of
PCA in estimating the covariance matrix of the GV indices and determining the PCs
[89–91]. Unfortunately, when the study was developed, only the data documented in
this chapter were available for testing the SPCA methodology. Further development of
48 Chapter 4 Parsimonious description of glucose variability by SPCA
the work, thus, should start from the extension of the datasets. With larger datasets,
in high sample size contexts, then, we could also consider to extend the initial pool
of indicators given as input to SPCA by inserting other well established GV metrics,
as, e.g., the mean of daily differences [92] and the continuous overlapping net glycemic
action [93] indices, as well as new indicators, e.g., those related to the concept of dy-
namic risk [94] or those derived in the nonlinear time-series analysis context [95–97].
As far as the SPCA algorithm is concerned, future works will consider the use of other
regression techniques to estimate the vector of sparse coefficients after the PCA step;
the elastic net approach [80], e.g., could be exploited instead of the LASSO constraint.
Chapter 5
Classification of glycemic control
and metabolic condition
5.1 Aim of the investigation
In Chapter 4, we used SPCA to select a small number of indicators able to well charac-
terize GV in diabetes. In the present chapter, we investigate if the linear combinations
obtained after PCA (i.e., PCs) and after LASSO (i.e., sparse PCs) can be exploited
in two classification problems, to discriminate between subjects with different quality
of glycemic control (Application 1 - Section 5.5) and between subjects with different
metabolic conditions (Application 2 - Section 5.6). In the first investigation, in partic-
ular, we had 55 T1DM subjects divided into three groups depending on their glycemic
control as assessed by an expert clinician from visual inspection of CGM profiles; in the
second investigation, we exploited CGM time-series acquired from 34 normal subjects
at high risk of developing T2DM, 39 IGT, and 29 subjects with diagnosed T2DM.
Both applications were managed by using linear and nonlinear support vector machine
(SVM) classifiers, an approach widely employed in machine learning [98, 99] and sum-
marily described in Section 5.2, which was recently used in the diabetes technology
area for improving hypoglycemia detection from CGM [100–102] and detecting incor-
rect measurements of CGM systems [103, 104]. To build the classifiers, we considered
PCs, sparse PCs, and single GV metrics as possible feature configurations. We per-
formed the investigation using both PCs and sparse PCs to assess if sparse PCs, that
allow to describe GV in a parsimonious fashion through a small number of indicators,
could provide an accuracy of classification comparable to that obtained with full PCs.
Moreover, we evaluated the performance obtained by considering single GV metrics
49
50 Chapter 5 Classification of glycemic control and metabolic condition
to test the hypothesis that a combination of indicators was effectively necessary to
perform well in the classification problems.
5.2 SVM classifiers
This section is devoted to an introductive presentation of SVMs, that provides a qual-
itative description of their design and use. A more detailed discussion can be found in
textbooks [98, 99], to which we refer the reader interested in this topic.
5.2.1 Formulation of the classification problem
Before entering the description of SVMs, we report some insights from statistical learn-
ing theory that help us in setting the problem of pattern recognition or classification.
In general, who resorts to learning algorithms is facing situations where two classes of
objects are given and a new object needs to be assigned to one of the two classes. This
means that we have a group of n data
(x1, y1), . . . , (xn, yn) ∈ H × {±1} (5.1)
with xi observations or patterns represented as vectors in the feature space H and yi
labels of the observations identifying the class to which each observation belongs, and
we want to generalize the unseen data points through a certain decision function
f : H → {±1} (5.2)
that predicts the class y ∈ {±1} of all the new unclassified patterns x ∈ H. The
mathematical formulation of the decision function depends on the specific method
adopted in the analysis, and the unknown parameters in it are optimized on a set of
pattern-label points called training set. After determining the optimal values of the
parameters in f , a different dataset, called test set, is used to asses the classifica-
tion performance, expressed, e.g., in terms of percentage of correctly classified points
(classification accuracy).
5.2.2 Optimal margin hyperplanes
In this section, we will show how to obtain the optimal decision function in the case of
linearly separable two-class training set. If we are given a feature space H (in which
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the dot product is defined), and a set of pattern vectors x1, . . . ,xn ∈ H belonging to
two classes labeled by +1 and −1, any hyperplane in H separating our data can be
written as
{x ∈ H | 〈w,x〉+ b = 0}, w ∈ H, b ∈ R (5.3)
where w is a vector orthogonal to the hyperplane, commonly referred to as the weight
vector in the machine learning literature. Our aim is finding the best hyperplane (w, b)
that separates the observations in the training set belonging to different classes, based
on a certain optimization criterion. To determine the optimal hyperplane, a decision
function fw,b : H → {±1} needs to be defined, and the pair (w, b) in it is determined
so that the labeled training examples are correctly classified and the margin of the
hyperplane is maximized. For a point (x, y) ∈ H × {±1}, the margin is defined as
ρ(w,b)(x, y) = y (〈w,x〉+ b)/||w|| (5.4)
and represents the distance from the point to the the separating hyperplane, with a
positive value if the point is correctly classified and a negative value otherwise. When
the entire training set is concerned, the margin of the hyperplane is the margin of
the closest observation correctly classified, and, as can be seen from Equation 5.4, it
depends on the length of the weight vector w. Loosely speaking, if we can separate
the data in our training set with a large margin (i.e., if the vector patterns are far
enough from the hyperplane), then we achieve a high generalization ability and have
reason to believe that we will do well on the test set. To confirm this idea, a number
of explanations exist [98]; an example is the insensitivity to pattern noise represented
in Figure 5.1, where it can be seen that if the optimal hyperplane has a margin ρ
and some noise bounded by r < ρ is added to each pattern, then the hyperplane will
correctly separate even the noisy patterns.
The hyperplane decision functions, thus, should be constructed such that they maxi-
mize the margin, and at the same time separate the training data with as few exceptions
as possible. Given these requirements, the optimization problem can be formalized.
We can assume that we are managing nonempty classes and that the point closest to
the hyperplane has a distance equal to 1/||w||, i.e., the margin of the hyperplane is
1/||w||. The condition of classifying correctly the training points implies that we have
to find a map of the form fw,b : H → {±1} satisfying
fw,b(xi) = yi (5.5)
52 Chapter 5 Classification of glycemic control and metabolic condition
Figure 5.1 Two-dimensional toy example of a classification problem [98].
which amounts to saying that the output of the decision function evaluated on each
pattern xi equals the real class to which the pattern belongs. If such a function exists,
then each pattern xi is correctly classified and its distance from the hyperplane is a
positive value equal to or greater than 1/||w||. This means that we can write the
following constraints
yi(〈xi,w〉+ b) ≥ 1, i = 1, . . . , n (5.6)
and use them in the formulation of the optimization problem to summarize the require-
ment of having the training observations correctly classified. Beyond this, we need to
say that we want to choose the separating hyperplane that has the greatest margin.
The objective function of our optimization problem, thus, should maximize the quan-
tity 2/||w||, that equals twice the margin of the hyperplane because we are considering
its symmetric version around the hyperplane. Maximizing 2/||w|| is the same as min-
imizing ||w||/2, and this leads to obtaining the optimal separating hyperplane as the
solution of the following constrained quadratic optimization problem
minimize
w∈H,b∈R
τ(w) =
1
2
||w||2 (5.7)
subject to the constraints 5.6. This is called the primal optimization problem, and a
graphic representation of its implementation to determine the optimal margin hyper-
plane is shown in Figure 5.2. Points represented in red, that lie exactly on the margin
of the hyperplane, are known as support vectors and are those where the constraints
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Figure 5.2 Optimal margin hyperplane classification for linearly separable two-
class training set. Support vectors are shown as red points.
5.6 are precisely met. Getting the solution of the primal optimization problem is possi-
ble, but not always easy. In the context of SVMs, the so-called dual problem is usually
derived, which is a problem that can be shown to provide the same solutions as the
primal problem, but turns out to be more convenient to deal with (we address the
interested reader to the textbook [98]).
5.2.3 Soft margin hyperplanes
In some scenarios, we would rather have an algorithm which can tolerate a certain
fraction of classification errors in separating the training data, instead of necessarily
looking for an optimal margin hyperplane. The approach that allows to implement this
kind of separation is based on the concept of soft margin hyperplane, and specifically
introduces some wights to the training data, called slack variables and defined as
ξi ≥ 0, i = 1, . . . , n, (5.8)
to relax the constraints 5.6 and get the following conditions
yi(〈xi,w〉+ b) ≥ 1− ξi, i = 1, . . . , n. (5.9)
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Clearly, by making ξi large enough, the constraint on (xi, yi) can always be met,
and thus to avoid the trivial solution where all ξi take on large values, we need to
penalize them in the objective function. To this end, the term
∑
i ξi is included in 5.7,
and the soft margin hyperplane is obtained by solving for some C > 0 the following
optimization problem
minimize
w∈H,ξ∈Rn
τ(w, ξ) =
1
2
||w||2 + C
n∑
i=1
ξi (5.10)
subject to the constraints 5.8 and 5.9. Whenever the constraint 5.9 is met with ξi = 0,
the corresponding point will not be a margin error. All nonzero slacks ξ, on the other
hand, correspond to margin errors, and the fraction of them that is accepted increases
with the second term of 5.10 and is managed through the positive constant C. As in
the separable case, the optimization problem can be shown to have a dual formulation
[98] that can be easily exploited to get the solution.
5.2.4 Nonlinear support vector classifiers and kernel trick
In the previous sections, we have only dealt with linear separators, and the case of
more general nonlinear decision surfaces has not been treated yet. Here, we discuss
the use of nonlinear support vector classifiers. In doing that, we observe that a set
of training data that is not linearly separable, if projected onto a higher-dimensional
space via some nonlinear transformation, has a high probability of being transformed
into a linearly separable set [98]. We can, thus, construct a nonlinear map φ(xi) to
transform the input data xi ∈ H into vectors of a higher-dimensional feature space, and
then separate the new data φ(xi) using linear decision surfaces obtained by solving the
optimization problem 5.10. Even if we can resort to problems of the same form as those
presented in the previous sections, however, this new formulation of the optimization
function requires the map φ to be defined and computed on each xi, and suffers from
the drawback that the calculation of dot products in high-dimensional spaces is a very
expensive procedure from a computational viewpoint. To overcome these limitations,
the so-called kernel trick to decrease the complexity of the optimization problem is
proposed. A kernel can be thought of as a symmetric function k : H×H → R that is
expressed as
k(xi,xj) = 〈φ(xi),φ(xj)〉 , (5.11)
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and corresponds to the dot product in a high-dimensional feature space via the map
φ. The most commonly exploited kernel functions are
〈xi,xj〉 (linear kernel) (5.12)
〈xi,xj〉d (polynomial kernel) (5.13)
e−γ||xi−xj ||
2
(radial basis function) (5.14)
but beyond their specific formulations, what makes them crucial in our treatment
is the possibility of using the relation 5.11 to rewrite the dot products among high-
dimensional vectors φ(xi) and simplify the optimization problem we are dealing with.
5.3 Datasets
In Application 1 (classification of the quality of glycemic control), we used three
datasets of CGM time-series collected from T1DM subjects. Two of the three are
those already used in the parsimonious description of GV, and thus we refer the reader
to Chapter 4 for details. The third dataset, made up of 22 profiles, was collected at
the Institute for Clinical and Experimental Medicine (Prague, Czech Republic) within
the same project and using the same protocol as the previous two. To perform the
classification problem, an expert clinician divided the subjects into three classes based
on the quality of their glycemic control as assessed from visual inspection of CGM pro-
files. Figure 5.3 shows a representative profile extracted from each class; comparing
the top (good control), middle (medium control), and bottom (bad control) panels, a
difference in the glycemic control of the three subjects can be already appreciated. To
help in identifying hypo and hyperglycemic events, thresholds at 70 and 180 mg/dL
are shown in the figure as dotted black lines; moreover, thresholds at 50 mg/dL rep-
resented as dotted red lines are reported to highlight the occurrence of SH. As can
be seen, the subject with good control experiences few hypo events, no SH episodes,
and some moderate hyper excursions. For subjects with medium and bad control, on
the other hand, some SH events can be detectable from the CGM profiles, and, in the
latter case, a sustained hyperglycemia can be seen as well.
In Application 2 (classification of the metabolic condition), 34 normal subjects at
high risk of developing T2DM, 39 IGT, and 29 T2DM subjects monitored using the
Medtronic R© iPro R© CGM System [85] were considered. As those used in the parsimo-
nious description of GV in T2DM, these data have been collected within the ongoing
EU FP7 project MOSAIC [86]. Examples of representative CGM recordings collected
56 Chapter 5 Classification of glycemic control and metabolic condition
Figure 5.3 Representative CGM time-series extracted from each class of glycemic
control according to the expert clinician classification; dotted black lines in the panels
represent hypo and hyperglycemic thresholds at 70 and 180 mg/dL, respectively;
dotted red lines represent the SH threshold at 50 mg/dL.
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Figure 5.4 Representative CGM time-series extracted from normal, IGT, and
T2DM classes; dotted black lines in the panels represent hypo and hyperglycemic
thresholds at 70 and 180 mg/dL, respectively; dotted red lines represent the SH
threshold at 50 mg/dL.
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in a normal, IGT, and T2DM subject are shown in Figure 5.4, top, middle, and bot-
tom panel, respectively. As for Application 1, the visual inspection of CGM profiles
allows to capture significant differences in the GV of the three subjects, highlighting
a sustained hyperglycemia experienced in T2DM, which decreases in the case of IGT,
and is almost absent in the normal profile.
5.4 Design of the classification study
This section provides details about the features used to characterize the observations
in our problems, the determination of training and test sets, and the estimation of
some relevant coefficients in the design of linear and nonlinear classifiers.
5.4.1 Feature configurations
The starting point used to derive our observations was the application of SPCA to the
dataset under analysis. This allowed us to manage two different feature configurations,
where PCs and sparse PCs were subsequently tested as features to build the classifiers.
Specifically, given that for all scenarios reported in Chapter 4 we saw that two PCs
were enough to explain most of the variance of the original 25 GV metrics, the first
two PCs provided by the application of PCA to the data matrix X conveniently built
up were considered as first feature configuration. Then, to assess if the parsimonious
combinations of indicators obtained from the application of the LASSO constraint to
each selected PC could provide comparable classification performances, the two sparse
PCs were considered as features too, defining the second analyzed configuration. Be-
yond the outputs obtained from SPCA, we decided to consider also each GV index as a
single feature to perform the classification, to investigate if a combination of indicators
was effectively necessary to comprehensively characterize GV and classify quality of
glycemic control and metabolic condition, or if single indicators by themselves could
already perform well in doing that.
5.4.2 Training and test sets
Once defined the feature configuration, we had to divide the whole observation set into
training and test sets. To do that, we followed the strategy reported in Figure 5.5.
We considered 80% of the available observations randomly extracted from the entire
dataset to build the training set, and the remaining 20% to build the test set. To avoid
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any bias due to the relatively small number of testing observations, the procedure was
repeated 100 times, and the median classification performance was then computed.
Figure 5.5 Definition of training and test sets in our SVM-based classification
problems. Dotted lines that divide the training set into four subgroups indicate that
a k-fold cross-validation was performed to determine the best SVM configuration.
Given that the implementation of SVM classifiers always depends on the regularization
parameter C and on some other parameters that appear in certain kernel functions
(e.g., d in the polynomial kernel or γ in the radial basis functions), an assessment of the
more convenient values to use has to be made each time on the specific observation
set. To this aim, in our implementation, we performed a k-fold cross-validation on
the training set (see Figure 5.5) and used a grid search approach to determine the
best values of our parameters. Based on this, we divided the training set into k = 4
subgroups of observations made up of approximately the same number of items, trained
the classifier with a specific configuration of parameters on k− 1 groups, and tested it
on the remaining one. By repeating the procedure for all the k subgroups, we could
get a median classification performance for each specific combination of parameters.
The best configuration was finally determined by keeping the parameterization that
maximized the median classification accuracy in the cross-validation setting.
5.5 Application 1: quality of glycemic control
5.5.1 Statistical analysis
We start the discussion on the obtained results by reporting in Figure 5.6 a graphic rep-
resentation of the set of observations (subjects) as depicted in the two two-dimensional
feature spaces that we considered in our investigation. In the figure, we can see the
placement of our samples in the PC (top panel) and sparse PC (bottom panel) fea-
ture space, where subjects are represented as blue circles if their glycemic control is
good, as green triangles if their control is bad, and as red crosses if their control is in
between. In both feature spaces, each vector is specified by a pair (x, y) of compo-
nents that correspond to the first and second PC/sparse PC, respectively. From the
inspection of the samples distribution, we can already observe that good and medium
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Figure 5.6 Representation of the observation set in the PC feature space (top
panel) and sparse PC feature space (bottom panel).
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control classes overlap significantly, and a separating surface which can generalize well
will be probably difficult to find in this case. Good/medium vs bad control classes,
on the other hand, seem to be separable quite enough. Moreover, at first sight, the
distribution of the observations in the sparse PC feature space seems to be not so
different from the distribution in the PC space, but to confirm the speculation that
the two scenarios behave similarly, we need to quantitatively compare the classification
performance achieved in the two cases.
Before entering the classification problem, we wanted to assess our choice of the feature
settings and be sure that a statistically significant difference between the three classes
was obtained for the considered features. To this aim, we computed a nonparametric
Kruskal-Wallis test for PCs and sparse PCs between the three classes. This test was
performed instead of one-way ANOVAs because one-sample Kolmogorov-Smirnov tests
used to check the null hypothesis of normally distributed samples provided p-values
< 0.05. Results form the Kruskal-Wallis tests are shown in Figure 5.7 (top panels
referred to PCs and bottom panels referred to sparse PCs). In all cases, p-values ob-
tained from the analyses resulted  0.005, meaning that there is at least one class for
each feature that behaves differently from the others. This suggested that our features
and feature spaces had been conveniently chosen.
5.5.2 Classification performance
Once established that first and second PC/sparse PC were significantly different be-
tween well, medium, and badly-controlled subjects, we could move to the actual clas-
sification problem. In practice, we dealt with three two-class classification problems
(i.e., good vs medium control, good vs bad, and medium vs bad), and for each of them
we exploited linear, polynomial, and radial kernel functions.
To determine the optimal values of the SVM parameters, we performed the grid search
described in Section 5.4. The best parameterization was chosen as the one that maxi-
mized the accuracy of classification in the cross-validation setting, and was then used
to train the classifier on the whole training set and determine the optimal decision
surface. This was made 100 times, with training and test sets randomly chosen, so
that any dependence of the results on the small number of testing points was avoided.
Classification performances obtained in the investigation are summarized in Table 5.1.
Accuracy of classification achieved from the application of the optimal SVM to both
training and test sets are listed, and values are reported as the median over the 100
repetitions performed with different training and test sets.
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Figure 5.7 Application 1: quality of glycemic control. Boxplots of first and second
PCs (top panels) and sparse PCs (bottom panels). On each box, the central mark
is the median, the edges of the box are the 25th and 75th percentiles, the whiskers
extend to the most extreme datapoints the algorithm considers to be not outliers,
and the outliers are plotted individually.
Results obtained in this scenario seem satisfactory. In all cases, the performances we
achieved are greater than 67%, and, in the good vs bad problem, we always got a 100%
classification accuracy. Looking at the tables, we can observe that in almost all cases
(except from the medium vs bad case with the radial kernel) linear kernels performed
well enough, and thus we don’t need to move to nonlinear configurations, and, above
all, the use of sparse PCs instead of PCs led to highly comparable results. Specifically,
in the good vs bad problem, performances of PCs and sparse PCs were exactly the
same; in the good vs medium, PCs outperformed sparse PCs in two out of three cases;
and in the medium vs bad, sparse PCs outperformed PCs in one out of three cases.
Also, no GV index as considered alone was able to achieve a classification accuracy
greater than 40% (results not documented for sake of space).
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GOOD VS MEDIUM CONTROL
PCs SPARSE PCs
LIN POL RAD LIN POL RAD
TRAINING 76% 76% 79% 76% 76% 76%
TEST 78% 78% 67% 72% 72% 77%
GOOD VS BAD CONTROL
PCs SPARSE PCs
LIN POL RAD LIN POL RAD
TRAINING 96% 100% 96% 96% 96% 96%
TEST 100% 100% 100% 100% 100% 100%
MEDIUM VS BAD CONTROL
PCs SPARSE PCs
LIN POL RAD LIN POL RAD
TRAINING 85% 85% 89% 85% 85% 85%
TEST 75% 75% 75% 75% 75% 75%
Table 5.1 Application 1: quality of glycemic control. Classification accuracy ob-
tained in the PC and sparse PC feature space from the three two-class classification
problems and the three exploited kernel functions (linear - LIN, polynomial - POL,
and radial - RAD).
5.6 Application 2: metabolic condition
5.6.1 Statistical analysis
As done for the first investigation, we start the discussion by reporting a graphic rep-
resentation of the set of observations as depicted in the PC (Figure 5.8 - top panel)
and sparse PC (Figure 5.8 - bottom panel) feature space. In the figures, normal sub-
jects are represented as blue circles, IGT as red crosses, and T2DM as green triangles,
and each vector in the feature space is specified by a pair (x, y) of components that
correspond to the first and second PC/sparse PC, respectively. Figure 5.8 shows that,
even if our classes overlap significantly, there are several subjects that have clearly
different positions in the feature spaces, and thus decision hyperplanes might perform
well in separating our groups of observations. Also, we can notice again that, at first
sight, what we can derive from the distribution in the sparse PC feature space is not
so different from what we see in the PC space. But again this speculation needs to be
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Figure 5.8 Representation of the observation set in the PC feature space (top
panel) and sparse PC feature space (bottom panel).
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confirmed by the final classification performances.
As for the Application 1, we computed a nonparametric Kruskal-Wallis test for PCs
and sparse PCs between the three classes (one-sample Kolmogorov-Smirnov tests used
to check the null hypothesis of normally distributed samples provided p-values < 0.05).
Results from the analysis are shown in Figure 5.9 (top panels referred to PCs and bot-
tom panels to sparse PCs). In all cases, p-values obtained from the analyses resulted
 0.005, and this confirmed again that our features had been conveniently chosen.
Figure 5.9 Application 2: metabolic condition. Boxplots of first and second PCs
(top panels) and sparse PCs (bottom panels). On each box, the central mark is the
median, the edges of the box are the 25th and 75th percentiles, the whiskers extend
to the most extreme datapoints the algorithm considers to be not outliers, and the
outliers are plotted individually.
5.6.2 Classification performance
Since PCs and sparse PCs were significantly different between normal, IGT, and T2DM
subjects, we could move to the actual classification problem. In practice, we dealt
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with three two-class classification problems (i.e., normal vs IGT, normal vs T2DM,
and IGT vs T2DM), and for each of them we exploited linear, polynomial, and radial
kernel functions.
Again, we performed the grid search described in Section 5.4, selected the best combi-
nation of parameters, and determined the optimal decision surface 100 times to avoid
any bias in the obtained results.
Classification performances obtained in the investigation are summarized in Table 5.2.
Accuracy of classification obtained on both training and test sets are listed, and values
are reported as the median over the 100 repetitions performed with different training
and test sets. We can observe that in general we were able to achieve a satisfactory ac-
curacy of classification. The are no performances lower than 71%, and, in some cases,
values greater than 90% were obtained. We can also notice that, again, sparse PCs
behave similarly to PCs, allowing to achieve the same classification accuracy on the
test set in all cases, and that GV index considered alone could not perform comparably
to PCs/sparse PCs (results not shown).
NORMAL VS IGT
PCs SPARSE PCs
LIN POL RAD LIN POL RAD
TRAINING 76% 78% 81% 74% 76% 79%
TEST 73% 73% 73% 73% 73% 73%
NORMAL VS T2DM
PCs SPARSE PCs
LIN POL RAD LIN POL RAD
TRAINING 88% 88% 90% 88% 88% 90%
TEST 92% 85% 85% 85% 92% 85%
IGT VS T2DM
PCs SPARSE PCs
LIN POL RAD LIN POL RAD
TRAINING 76% 83% 83% 76% 83% 83%
TEST 71% 71% 71% 71% 71% 71%
Table 5.2 Application 2: metabolic condition. Classification accuracy obtained in
the PC and sparse PC feature space from the three two-class classification problems
and the three exploited kernel functions (linear - LIN, polynomial - POL, and radial
- RAD).
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5.7 Conclusions
In this chapter, we exploited the use of the outputs obtained from SPCA (i.e., PCs and
sparse PCs) as tools for the classification of the quality of glycemic control (Application
1) and of the metabolic condition (Application 2) of disordered subjects. Specifically,
we developed SVM-based linear and nonlinear classifiers, and attempted to solve the
two classification problems using the first two PCs and their sparse representations as
features to build the classifiers.
Results obtained from this investigation were satisfactory. With the relevant percent-
ages of classification accuracy achieved, we can speculate that PCs and sparse PCs
could be exploited, e.g., within glucose sensors, to characterize the glycemic condition
of disordered subjects, providing feedback about the ongoing therapy and alerts about
the possible transition to more dangerous metabolic diseases (e.g., from a condition at
risk of T2DM to T2DM). Moreover, given that equal performances were achieved with
PCs and sparse PCs, a confirmation of the real capability of SPCA of parsimoniously
describing GV in diabetes was provided.
It is also worth observing that PCs and sparse PCs outperformed any GV index as
considered alone in solving our classification problems, and this suggests that a combi-
nation of metrics is effectively necessary to well characterize GV. Nonetheless, it could
be pointed out that combinations of indicators with a number of predictors smaller
than five could work as well. This kind of investigation could be matter of future works,
but it is important to stress that the approach to get the combinations of metrics will
be exactly the same, exploiting the SPCA-based strategy presented here.
A limitation of the study is related to the relatively small number of subjects that
could be used in the test sets. This condition led us to repeat the analysis 100 times,
without being able to provide a final formulation of the SVM classifier. With larger
datasets, it could be possible to isolate a certain amount of subjects within a test set,
and identifying a definitive version of the SVM that could be formalized and exploited
in practice to solve classification problems like those proposed here. This issue will be
addressed in future works.
From an algorithmic viewpoint, developments of this investigation shall assess the im-
plementation of classification strategies different from SVMs and move from two-class
classification problems to multi-class ones, exploiting the common one-vs-one and one-
vs-rest SVM approaches or other techniques.
Finally, to strengthen the results obtained in Application 1 and make them more con-
sistent, a larger number of expert clinicians should be asked to perform the initial
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classification of the quality of glycemic control. This would render the study less
dependent on potential subjective evaluations.
Chapter 6
Conclusions
6.1 Summary of the results
GV is widely considered as a risk factor for the development of long-term complica-
tions from diabetes, and a number of indicators have been developed to quantitatively
measure it from either SMBG or CGM profiles.
The first problem considered in this dissertation was extending the use of some GV
indices designed and validated only from SMBG data, to CGM recordings. In particu-
lar, we performed this kind of analysis on the well-known LBGI and HBGI, indicators
that, as computed from SMBG time-series, have been shown to be predictive of sig-
nificant glycemic events and allow to classify the risk of hypo and hyperglycemia of
diabetic subjects. The proper use of LBGI and HBGI on CGM signals has been here
enabled by developing suitable transformation functions that adapt the indicators to
the characteristics of CGMs. The study was designed based on a dataset of 28 T1DM
subjects monitored for up to four weeks with both SMBG and CGM systems. The
alternate versions of LBGI and HBGI proposed allow references to previous works and
clinically relevant cutoff values, and extend the possibility of exploiting these indica-
tors to classify the overall quality of glucose control from CGM time-series.
The second problem we dealt with in this thesis concerned the fact that several indi-
cators to quantify GV are available and the information conveyed by them is usually
redundant. Therefore, we proposed the use of SPCA to provide a parsimonious de-
scription of GV in both T1DM and T2DM. Specifically, the approach was applied to
a pool of 25 literature GV indices evaluated on 33 T1DM and 13 T2DM CGM time-
series, and allowed to select a reduced subset of up to 10 indicators that could save
more than 60% of the original variance in both scenarios. Of note is that a small group
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of metrics was shared by the parsimonious sets of indicators in T1DM and T2DM, sug-
gesting that some GV indices could be particularly representative of GV in diabetes
regardless of the specific type of disease.
The third investigation developed in the study was aimed at managing the outputs
of SPCA (i.e., PCs and sparse PCs) to develop a GV-based SVM classifier of the
metabolic state of normal and diabetic subjects. Specifically, we attempted to clas-
sify the quality of glucose control of 55 T1DM subjects, and the actual metabolic
condition of 34 subjects at high risk of developing T2DM, 39 IGT subjects, and 29
subjects with T2DM diagnosed. Results obtained from the analysis showed high per-
centages of classification accuracy in both scenarios, with 100% accuracy obtained in
the classification of good vs bad glycemic control subjects with both PC and sparse
PC feature configurations, and 92% accuracy in the classification of normal vs T2DM
subjects with the linear kernel in the PC feature space and with the polynomial in the
sparse PC one. The similar classification performance obtained with PCs and sparse
PCs strengthened our speculation that SPCA can be used as a technique to obtain
parsimonious descriptions of GV in diabetes.
6.2 What’s next?
Further developments of the work presented in this dissertation will concern, first of
all, the enlargement of the considered datasets. With a larger number of observations,
the number of rows in the data matrix given as input to PCA and the ratio between
number of observations and number of variables would increase, leading to a more
robust estimation of the covariance matrix of the GV metrics and, thus, of the final
SPCA results. Given this observation, having additional CGM recordings is also a
condition necessary for extending the initial pool of indicators given as input to SPCA
and providing an established linear combination of GV indices to be considered as a
gold-standard metric in the characterization of GV. With a larger dataset, then, we
would be able to avoid the necessity of 100 repetitions of the classification strategy
proposed in Chapter 5 and we could provide a final description of the best SVM
formulation to classify quality of glycemic control and metabolic condition, allowing a
possible practical implementation and use of the strategy, e.g., within glucose sensors.
From a methodological viewpoint, multi-class problems could be managed instead of
two-class ones and, beside classifiers developed using SVM, also other less sophisticated
approaches, such as the k-nearest neighbors, could be investigated; simultaneously,
approaches different from the LASSO constraint (e.g., elastic net regression) could be
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assessed in performing the variable selection task after the PCA step within SPCA.
Results obtained from different techniques in both cases could be compared, suggesting
different interpretations of the problem or strengthening the results obtained so far.
Concerning the correction of LBGI and HBGI, further developments of the study will
be focused on the assessment of the transformation functions with other CGM systems,
to allow the application of the indicators in several scenarios involving the exploitation
of different CGM devices. Also, investigating how much the transformation functions
depend on the different sampling frequency of SMBG and CGM, and how much on
possible sensor inaccuracy could be matter of future studies.
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